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Immunotherapy is an increasingly attractive treatment option for many cancers 
because it has the potential to reverse the immunosuppressive tumor 
microenvironment, target tumor antigens, and maintain a long-lasting anti-tumor 
response. Brain cancers are top candidates for such innovative therapies because 
current standard-of-care is limited to surgery, radiation, and chemotherapy; surgery 
often fails to resect 100% of the tumor, and delivery of chemotherapeutic drugs to the 
brain is very inefficient due to the blood-brain barrier’s tightly regulated 
microenvironment. New immunotherapies for colon cancers are also being explored 
because of the difficulties of resection surgery and the plethora of adverse effects 
associated with current targeted therapies and immune checkpoint blockade due to 
systemic or oral administration. Thus, drug delivery vehicles are being designed to carry 
antigens and other immunostimulatory molecules directly to tumors or tumor-draining 
lymph nodes for site-specific treatment that is minimally invasive and reduces off-target 
side effects.  
Within this dissertation, we explored (1) the therapeutic ability of synthetic high 
density lipoprotein (sHDL) nanodiscs to deliver neoantigens for glioblastoma multiforme 
(GBM) to exert specific anti-tumor effects, (2) whether immunogenicity of colon 






is retained, and (3) the ability of sHDL nanodiscs to co-deliver chemo- and immuno-
therapeutic entities to colon adenocarcinoma tumors.   
In the first project, we found that delivery of neoantigens by sHDL nanodisc was 
significantly more effective compared to delivery of soluble neoantigens in neoantigen-
specific CD8+ T cell production, tumor growth reduction, and survival prolongation in 
murine GBM models.  These anti-tumor effects were augmented by the addition of 
immune checkpoint blockade anti-programmed death receptor ligand 1 (PD-L1), and 
neoantigen-loaded sHDLs in combination with anti-PD-L1 reversed immunosuppression 
within the tumor microenvironment by significantly increasing CD8+ T cells and 
decreasing their PD-1 expression along with regulatory T cell (Treg) frequencies within 
the tumor.  
In the second project, we showed that we were able to simplify our formulation 
process for neoantigen-loaded sHDL through chemical modification of two neoantigen 
peptides using short chain poly(ethylene glycol) (PEG) and pre-made lipoprotein films. 
We verified that the simplified PEGylated formulations induced neoantigen-specific 
CD8+ T cell expansion similar to our traditional formulations.  Although prophylactic 
vaccination did not slow MC38 colon adenocarcinoma tumor growth or extend overall 
survival equally between the two neoantigens Reps1 and Adpgk, we did see that 
PEGylated formulations and traditional formulations exhibited anti-tumor efficacy similar 
to each other. Together, these results indicated that nanovaccine synthesis could be 
streamlined for clinical translation.  
In the third project, we demonstrated the therapeutic advantage of co-delivering   






adenocarcinoma model.  In vivo evaluation of docetaxel-loaded sHDL (DTX-sHDL) co-
loaded with CpG oligonucleotide revealed that CpG significantly improved the antitumor 
efficacy of DTX, suppressing tumor growth and prolonging survival in mice treated with 
DTX-sHDL/CpG as compared to mice treated with DTX-sHDL or DTX alone. Complete 
responses were achieved in two of the seven mice treated with DTX-sHDL/CpG without 
inducing any systemic toxicities, supporting the hypothesis that combination therapy 
with an immuno-stimulatory component would augment the antitumor efficacy of 
chemotherapy alone. 
In full, this dissertation (1) exposed a highly efficacious, tumor-specific, and 
personalized nanovaccine design for improving treatment of patients with Glioblastoma 
multiforme (GBM), (2) streamlined the neoantigen-sHDL nanovaccine formulation 
process for clinical translation, and (3) proposed an efficient method for co-delivery of 
chemo- and immuno-therapeutic entities for site-specific, non-toxic cancer treatment 
using sHDL nanodiscs. We believe that sHDL nanodiscs are versatile drug delivery 





Chapter 1. Introduction 
Cancer immunotherapy aims to harness the body’s immune system to target and kill 
tumor cells. A wide variety of cancer immunotherapies have been explored over the 
years, including immune checkpoint blockade antibodies, cellular therapies based on 
dendritic cells (DCs) and T lymphocytes, and therapeutic vaccines. In the clinic, 
antibodies against immune checkpoints cytotoxic T lymphocyte-associated antigen-4 
(CTLA-4) and programmed cell death receptor-1 (PD-1) have been game-changers1-5.  
 
 
Figure 1-1. Immune checkpoint inhibitors can block tumor cell or dendritic cell ligation with PD-1 on T cells, thereby 
preventing T cell death and preserving anti-tumor immunity via major histocompatibility complex (MHC)-tumor antigen 
interaction with T cell receptors (TCRs). Created with BioRender.com.  
These antibodies are designed to liberate T cells from immunosuppression mediated by 
the CTLA-4 and PD-1 pathways, promoting potent and durable T cell responses that 
can eliminate tumors and put patients in remission3,6. However, only a subset of 
patients (generally 10-40%) currently benefits from immune checkpoint blockade in the 
clinic3,6. While co-administration of both anti-CTLA-4 and anti-PD-1 antibodies can 
synergistically exert anti-tumor effects, serious immune-related toxicities have been 
observed. One clinical study reported that 53% of patients treated with the dual anti-
CTLA-4/PD-1 immunotherapy experienced grade 3 or 4 adverse events, including 
hepatic, gastrointestinal, and renal disorders7. Thus, there is strong interest to improve 
patient response rates to cancer immunotherapy in a safe and effective manner. One 
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potential avenue for achieving these goals would be combining immune checkpoint 
blockers with emerging treatment modalities, such as cellular therapies and therapeutic 
vaccines8-17. Cellular therapies with patient-derived DCs involve ex vivo differentiation of 
peripheral blood monocytes into DCs, followed by pulsing with tumor-associated 
antigens (TAAs) to create a rich population of mature DCs presenting TAA peptides on 
major histocompatibility complexes (MHC). These DCs can then be infused back into 
the patient for T cell activation and tumor cell killing18,19. Alternatively, T cells can be 
isolated from the patient’s blood, and specific T cell populations can be enriched or 
genetically modified to promote anti-tumor efficacy. Unfortunately, production of MHC-
peptide-presenting DCs and tumor-specific T cells are quite labor-intensive, and their 
yield and quality are variable. Thus, the field is moving towards acellular cancer 
vaccines and combination immunotherapies.  
1.1. The roles of antigens in developing cancer immunotherapies 
A major trigger for T cell activation is antigen cross-presentation by antigen-
presenting cells (APCs) upon pathogen processing. This mechanism involves the 
endocytosis and breakdown of pathogens or pathogen products by APCs, which can be 
macrophages or dendritic cells. Once antigen peptide products are released within the 
cell and coupled to MHC molecules, the MHC-peptide pair moves to the cell surface for 
antigen presentation. Different T cells respond to antigen presentation with T cell 
receptors (TCRs) specific for MHC-I (CD8+) or MHC-II (CD4+) molecules. Historically, it 
was believed that APCs could process only endogenous antigens by the MHC-I 
pathway and only exogenous antigens by the MHC-II pathway. They discovered that 
this peptide processing was not so black-and-white after collecting data over the last 40 
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years that showed the effective cross-presentation of an MHC-I-associated peptide, 
OVA257-264, derived from the chicken egg protein Ovalbumin by dendritic cells 20. 
Today, ovalbumin and its immunogenic peptide, commonly referred to by its amino acid 
sequence SIINFEKL, are used extensively in immunological studies involving CD8+ T 
cell activation. This is important because it has given scientists a model for APC cross-
present exogenous antigens, such as tumor antigens, to and subsequent activation of 
antigen-specific CD8+ T cells.  
This enhanced understanding of cross-presentation and T cell activation has been 
fundamental in developing cancer immunotherapies. Because CD8+ T cells are cytolytic 
and anti-neoplastic and rely on APCs to activate and cross-present antigens to them, 
researchers have focused on activating and recruiting antigen-specific CD8+ T cells to 
the tumor microenvironment to eradicate malignant cells expressing the antigens that 
the T cells recognize. To this end, adoptive T cell therapy (ACT), the process of 
manipulating T cells ex vivo for subsequent transfer back into patients, has recently 
gained much attention and become one of the mainstream cancer immunotherapies 
after immune checkpoint therapy21. Three categories of ACT have been established: 
TIL, TCR, and CAR-T. Tumor infiltrating lymphocytes (TILs) from patients’ own tumor 
biopsies expanded ex vivo by IL-2 stimulation were the first type of therapeutic T cells to 
be studied. However, TILs have shown limited efficacy, prompting the development of 
other categories of ACT. The other two strategies, TCR and CAR-T, use peripheral T 
cells transfected with either a specific gene encoding T cell receptor (TCR) of a target 




Figure 1-2. General process for generating CAR-T cells. Created with BioRender.com. 
In contrast to TCR transgenic T cells, the extracellular single chain variable fragment 
(scFv) of CAR-T cells binds to antigens independent of MHC, enabling CAR-T cells to 
target a wider range of tumor-associated antigens. The efficacy of CAR-T therapies in 
treating hematological malignancies has resulted in two FDA-approved CAR-T cell 
therapeutics, Tisagenlecleucel and Axicabtagene ciloleucel, for the treatment of acute 
lymphoblastic leukemia (ALL) and large B-cell lymphoma, respectively22. However, 
when a target antigen is shared by normal and cancer cells, transferred T cells can 
cause severe on-target-off-tumor toxicity21. Therefore, many groups are working to 
generate CAR-T cells that are more specific to cancer cells while minimizing side effects 
and increasing efficacy. One approach is to develop patient-tailored neoantigen-specific 
T cells via genetic engineering. Indeed, it has been found that a higher number of 
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putative neoantigens in tumors leads to better prognosis for patients receiving ACT23, 
suggesting that ACT could become more efficacious when T cells are targeted against 
neoantigens. A recent study showed that after T cells were transduced with a gene 
encoding an HLA- and mutation-specific TCR for a shared neoantigen that harbored a 
H3.3K27M mutation (amino acid substitution from lysine (K) to methionine (M) at 
position 27 of H3.3) in diffuse intrinsic pontine gliomas, the TCR therapy was able to 
inhibit tumor growth in a xenograft mouse model24.  
Another limitation of current ACT is generating a sufficient number of cells ex vivo 
prior to infusing cells to patients. This procedure is labor-intensive and requires 
specialized skills, thus limiting the availability of ACT to only a few institutions 
worldwide. One potential engineering solution is in situ transfection of CAR genes in 
peripheral T lymphocytes (Figure 1-3)25.  
 
Figure 1-3. Formulation schematic for loading polymeric nanoparticles with CAR genes to enable T cell transfection 
and subsequent transcription. Figure taken from 25 
Circulating T cells have been targeted by CD3-directed nanoparticles carrying genes for 
CD19 CAR and piggyBac for sustained transcription, leading to significantly improved 
survival of mice inoculated with Eμ-ALL01 leukemia cells. This strategy targeted to 
Figure 1. Design and manufacture of lymphocyte-programming nanoparticles
a, Schematic of the T-cell-targeted DNA nanocarrier used in our experiments. The inset 
shows a transmission electron micrograph of a representative nanoparticle. Scale bar, 100 
nm. Also depicted are the two plasmids that were encapsulated into the nanoparticles; these 
encode an all-murine 194-1BBz CAR and the hyperactive iPB7 transposase. EF1A, 
eukaryotic translation elongation factor 1 alpha 1; BGH PA, bovine growth hormone 
polyadenylation signal; ampicillin resistance gene; ORI, origin of replication. b, Diagram 
describing the fabrication of the poly(ͤ-amino ester) nanoparticles. Also shown are the 
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circulating T cells may be applicable for generating neoantigen-specific T cells; 
however, indirect immune activation and biocompatibility of the proposed system should 
be carefully assessed. Another potential strategy to address the current limitations of 
ACT is to develop artificial antigen presenting cells (aAPC) for more efficient expansion 
of functional T cells during ex vivo proliferation. Paramagnetic nanoparticles have been 
designed with agonistic antibodies for providing signals 1 and 2 to enhance T cell 
activation and proliferation26. Interestingly, once magnetic field was applied, these 
nanoparticles tethered on the cell surface were clustered, mimicking the signal 
microcluster observed during the activation of T cells. This allows for on-demand control 
of costimulatory molecules. Similarly, activation and proliferation of CD8+ T cells have 
been induced with a carbon nanotube-based platform presenting MHC-I molecules and 
anti-CD28 antibody and PLGA nanoparticles delivering IL-227. Notably, this system 
required a thousand-fold less amount of soluble IL-2 to obtain comparable number of T 
cells as commercially available Dynabeads. Alternatively, mesoporous silica micro-rods 
carrying IL-2, anti-CD3 Ab and peptide-loaded MHC have been developed as an aAPC 
system (Figure 1-4), which promoted a five-fold greater expansion of antigen specific 
CAR-T cells, compared with Dynabeads28. Interestingly, a slow-release profile of IL-2 
from the platform induced less exhausted T cells and consistent CD4:CD8 ratio, 




Figure 1-4. (a) Formulation design of mesoporous silica micro-rods carrying IL-2, anti-CD3 Ab and peptide-loaded 
MHC to form aAPC scaffolds (b) Dynamic simulations of aAPC scaffold interacting with T cells in two different 
settings depending on which molecules were loaded into the micro-rods. Figure taken from 29.  
Maintenance of the viability of adoptively transferred T cells and their tumor 
infiltration are additional challenges for ACT, especially for improving its efficacy against 
solid cancers. Due to the immune-suppressive nature of the tumor microenvironment, it 
is critical that the transferred T cells proliferate sufficiently and home to tumors. To 
address this, the surfaces of CD8+ T cells have been modified with lipid-based 
nanoparticles carrying IL-15 super-agonist and IL-21 cytokines for potent proliferation of 
T cells30. Such localized delivery of cytokines enhanced survival and proliferation of T 
cells after adoptive transfer into cognate antigen-expressing tumor-bearing mice and 
reduced systemic immunomodulatory effects typically associated with bolus 
administration of free cytokines. In a similar approach, lipid-based nanoparticles 
carrying topoisomerase I poison SN-38 have been attached on the surfaces of CD8+ T 
cells31. Notably, these CD8+ T cells were expanded ex vivo while maintaining their LN-
homing receptors CD62L and CCR7. This strategy allowed efficient homing of 
transferred T cells to LNs, increasing delivery of SN-38 to LNs by 90-fold as compared 
with bolus injection of the drug at 10-fold higher dose and extending animal survival in a 
lymphoma model31. Alternatively, adoptively transferred T cells have been targeted in 
Figure 1. Antigen-presenting cell-mimetic scaffolds (APC-ms)
(a) Process for preparing APC-ms from mesoporous silica micro-rods (MSRs). (b) For 
polyclonal T cell expansion, activating antibodies against CD3 (ͣCD3) and CD28 (ͣCD28) 
are attached (left). For antigen-specific T cell expansion, peptide-loaded MHC (pMHC) and 
ͣCD28 are attached (right). In both, IL-2 was released over time, resulting in paracrine 
delivery to local T cells. (c) Representative microscopy of MSRs (left), fluorophore-tagged 
phospholipid (middle), and co-localization of MSRs and lipids (right). Scale bar=200 µm. 
(d) Retention of lipid on MSRs over time in either PBS or RPMI-1640 containing 10% 
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situ with antibody-decorated liposomes carrying IL-2 or TGF-b inhibitor, which promoted 
proliferation of T cells while reversing immune-suppressive tumor microenvironment32,33. 
Thus, these biomaterial strategies allow specific targeting of drugs to transferred cells 
and avoiding off-target immunomodulation, thereby safely augmenting T cell therapies.  
1.1.1. The promise of neoantigens in personalized cancer immunotherapy 
Recent advances in genomics and proteomics are shedding new light on the tumor 
mutanome, revealing that every tumor has a unique set of driver and passenger 
mutations34-36. Tumor cells expressing mutated proteins present these neoantigens as 
new epitopes in the context of MHC molecules. Expression of neoantigens is, by 
definition, restricted to tumor cells as opposed to TAAs with shared expression among 
healthy and tumor cells. Thus, immunotherapy directed against neoantigens may allow 
for specific immunological targeting of tumor cells without self-tolerance. As such, 
neoantigens may hold the key to designing personalized immunotherapy, allowing us to 
capitalize on rich genomic and proteomic bioinformatics data to customize cancer 
treatment for patients. The prospect of customizing cancer treatment to individual 
patients with neoantigen-directed immunotherapy has recently galvanized the field of 
cancer immunotherapy34-36. Identification of neoantigens begins with whole exome DNA 
and RNA sequencing of tumor cells. Subsequently, a number of filters can be used in 
the neoantigen identification pipeline to narrow the search, such as predicted 
proteasome processing, MHC class I and II binding affinities, and confirmation with 
mass spectrometry analysis of immunoprecipitated peptides. Once top neoantigen 
candidates are selected, they can be screened further for the presence of neoantigen-
specific T cells in patient specimens. First demonstrated in murine models of cancer37-
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40, the concept of neoantigen-based personalized immunotherapy quickly progressed to 
where their potency and efficacy have been demonstrated in proof-of-concept Phase I 
clinical trials with small cohorts of advanced melanoma patients 41,42.  
 
Figure 1-5. Comparative expression of tumor-associated antigens (TAAs, red circle) and tumor-specific antigens 
(neoantigens, teal). TAAs are expressed by both normal and tumor cells while neoantigens are solely expressed by 
tumor cells. Created with BioRender.com.  
A series of recent papers has showcased striking therapeutic potential of 
neoantigen-based vaccines. One of the first comprehensive studies that explored 
vaccination with neoantigen peptides was reported by Castle et al. in 201237. Using next 
generation exome sequencing, the authors identified over 900 nonsynonymous point 
mutations in B16F10 murine melanoma cells, over half of which were expressed in 
tumor cells. Mutated peptide sequences were filtered by MHC-binding prediction tools, 
and 50 peptides were selected for immunogenicity screening in mice. Subcutaneous 
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injection of neoantigen or wild type peptides together with polyinosinic:polycytidylic acid 
(poly(I:C), a Toll-like receptor-3 agonist) adjuvant induced IFN-γ-specific T cell 
responses with 16 out of 50 peptides, but only 5 of the 16 were specific to neoantigen 
over wild type stimulation. When tested in a therapeutic setting, neoantigen vaccination 
slowed the growth of B16F10 tumors, compared with treatment with poly(I:C) alone and 
no treatment37. In 2014, tumor exome sequencing was employed in conjunction with 
mass spectrometry for the first time to nominate neoantigens. In a hind limb MC38 
tumor model, mice vaccinated intraperitoneally with long neoantigen peptides (25-30 
amino acid long) together with anti-CD40 and poly(I:C) adjuvant significantly reduced 
tumor growth and increased tumor-infiltration of neoantigen-specific CD8+ T cells as 
compared with mice vaccinated with anti-CD40 and poly(I:C) alone38. In 2017, results 
were reported from the first-in-man Phase I clinical in which six advanced melanoma 
patients were treated with neoantigen peptide vaccines after surgical resection35. 
Briefly, each patient received 7 doses of a mixture of 20 different neoantigen peptides 
and poly(I:C). Importantly, neoantigen vaccination induced CD4+ and CD8+ T cells 
targeted against 58 (60%) and 15 (16%) of the 97 unique neoantigens across 6 
patients. Four patients had no recurrence at 25 months after vaccination, and two 
patients had complete tumor regression after treatment with anti-PD-1. This seminal 
paper showed potential of personalized neoantigen vaccination, especially in 
combination with immune checkpoint blockade, which can unleash the full cytotoxic 
potential of neoantigen-specific T cells. In contrast to vaccination with shared tumor 
antigens, neoantigen vaccinations can reduce the likelihood of immune tolerance as 
neoantigens are solely and uniquely expressed by individual patients’ tumor cells. 
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These papers have underscored the clinical applicability of personalized neoantigen 
vaccines as a new therapeutic strategy for long-term protection against tumor relapse 
and metastasis. In this dissertation, neoantigens were pursued as a tool for cancer 
immunotherapy in the context of Glioblastoma multiforme (GBM), a stage IV brain 
cancer, and Colon adenocarcinoma due to the lack of truly effective therapies for these 
cancers currently available in the clinic. Before discussing the current state of these 
cancers and the design of our neoantigen immunotherapies, the current and potential 
delivery options for neoantigens must be reviewed.  
1.1.2. Acellular neoantigen delivery systems 
As highlighted in the section 1.1.1, these tantalizing results generated with 
neoantigen vaccines have galvanized the field for personalized immunotherapy; 
however, there are numerous challenges to overcome to produce potent anti-tumor 
efficacy with neoantigens in a safe, effective, and personalized manner. In particular, 
new delivery strategies are needed to enhance transport of neoantigens together with 
adjuvant molecules to LNs. Amino acid composition of neoantigen peptides can have 
significant effects on their isoelectric points, and administration of a cocktail of soluble 
peptides can lead to precipitation, deposition in off-target tissues, or dissemination 
through the systemic circulation without preferential targeting to lymphoid tissues. The 
end result is that only a minor fraction of the peptide dose reaches the target lymphoid 
tissues, limiting the overall vaccine efficacy. While several groups have reported 
enhanced immunogenicity with peptide vaccines when they include oil-based adjuvants, 
such as Montanide, to create water-in-oil formulations that form depots for slow release 
of antigen peptides43,44, these formulations are often associated with adverse effects, 
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such as abscess formation and sustained inflammation at the injection site, leading to 
sequestration and deletion of antigen-specific T cells at the injection site45-47. Therefore, 
neoantigen vaccine platforms should be designed to maximize antigen delivery to LNs 
while considering the aqueous solubility and physicochemical properties of neoantigen 
peptides. In addition, co-localized delivery of antigens and adjuvant molecules to the 
same intracellular compartments (i.e. endosomes with TLRs) within APCs is needed to 
achieve robust T cell responses48,49. Moreover, an ideal vaccine platform for 
neoantigens should be versatile yet easy to manufacture since personalized vaccine 
products requires rigorous quality control, patient-to-patient consistency, and 
adaptability to each patient.  
 
Figure 1-6. Guidelines for drug delivery vehicle design to target lymph node or APC delivery. Particles that are <30 
nm in size, negatively charged, and decorated with high densities of polymer are more likely to drain directly through 
the lymphatic vessels to the lymph node than to be phagocytosed by APCs. Figure taken from 50 
In this respect, nanovaccines are gaining much momentum in the field51 as 
nanoparticles with an optimal size (10-100 nm) for lymphatic trafficking (Figure 1-6) are 
efficient carriers for targeted delivery of antigens to APCs31,52. “Albumin-hitchhiking” 
offers an alternative approach to antigen and adjuvant delivery. Taking advantage of 
serum albumin’s biophysical properties, cellular interactions, and molecular transport 
negatively charged hyaluronic acid [30]. Therefore, vehicles carrying a
net positive charge tend to become trapped in the extracellular matrix
of interstitium and cannot drain freely into lymphatic capillaries.
Neutral or negative charge usually promotes the interstitial transfer of
vehicles [31], although there are a few exceptions [32]. Since vehicles
move through the interstitium via water channels, covering vehicles
with hydrophilic materials may lead to more e!cient movement than
covering them with hydrophobic materials [33]. Factors that a"ect
interstitial #uid #ow, such as interstitial pressure, can also a"ect lym-
phatic transport. Since interstitial pressure and #uid #ow rate vary at
di"erent injection sites, the choice of site can have important im-
plications for lymphatic transport [26]. Concretely, the relatively high
interstitial pressure and rate of lymph #ow in the dermis mean that
intradermal injection leads to greater lymphatic uptake than in-
tramuscular or subcutaneous injection [34,35]. The relatively high in-
terstitial pressure in the foot means that injection there leads to greater
lymphatic transport than injection into the #ank [36]. Co-administering
the vaccine with agents that increase interstitial oncotic pressure, such
as albumin [37], dextrans [38], bradykinin or histamine [39], also
promotes lymphatic uptake and transport. Modifying vehicles with
targeting agents that bind targets expressed on lymphatic endothelial
cells can also promote lymphatic uptake [40,41].
Another method to improve delivery of vaccine vehicles to lymph
nodes takes advantage of the fact that, in addition to a"erent lymphatic
vessels, there are other types of a"erent vessels that drain into lymph
nodes. Vehicles can be targeted to high endothelial venules (HEVs),
which support high levels of lymphocyte extravasation from the blood
into lymphoid tissues [42]. Modifying tacrolimus-loaded microparticles
with MECA79 antibody against addressin on HEVs increased the ac-
cumulation of microparticles in draining lymph nodes after intravenous
injection [43]. Further development of this method will require further
insights into how vehicles enter lymph nodes via HEVs, since most re-
search has focused on a"erent lymphatic vessels.
4. Uptake of vaccine vehicles by APCs in the ly ph node
Delivery of vaccine-loaded vehicles to lymph nodes on its own is
insu!cient for eliciting strong immune responses, as vehicles may
simply pass around the outside of the lymph node via the subcapsular
sinus and leave directly via the e"erent lymph [26]. Vaccine uptake by
APCs in the lymph node and subsequent activation of these APCs is
crucial for triggering powerful adaptive immunity. Designing vaccines
that can be e!ciently internalized by APCs comes with a dilemma:
vehicle characteristics that promote lymph node drainage often hinder
internalization by APCs (Fig. 2). For example, vehicles with mean
diameters of 20 or 45 nm drain into lymph nodes much more e!ciently
than 100-nm vehicles [44], but smaller vehicles are taken up by DCs
less e!ciently than larger ones [45]. In fact, a study with 30-nm ve-
hicles found that a substantial proportion was not taken up by APCs in
the draining lymph nodes, and the vehicles could be detected at sub-
stantial concentrations in the peripheral blood even up to 12 h after
intradermal injection [46].
Optimizing surface modi$cations and surface charge of vaccine
vehicles can be challenging. For example, PEGylation promotes vehicle
movement through the interstitium, but it inhibits phagocytosis by
APCs [47]. In addition, positive charge on the vehicle can promote
internalization by APCs more than neutral or negative charge [48], but
it increases the risk that the vehicle will be trapped in the interstitium
before it can arrive at the lymph nodes. Such trapping may help explain
why several ligand-based surface modi$cations of vehicles facilitate
uptake by APCs in vitro but do not induce potent immune responses in
vivo. For example, adding mannose to PEGylated liposomes increased
OVA uptake by bone marrow-derived dendritic cells (BMDCs) and en-
hanced their maturation [49]. Adding antibodies against DC surface
receptors (e.g. CD40, DEC-205, CD11c) to PLGA nanoparticles en-
hanced uptake by DCs and T cell activation [50]. However, these two
approaches elicited less than impressive immune responses in vivo
[49,50]. At the same time, these approaches increase the cost and
complexity of vehicle production and make their in vivo behavior more
di!cult to predict and control. Since DCs show intrinsically high pha-
gocytosis of particles and are present in large numbers in lymph nodes,
it may be possible to target these cells in lymph nodes by optimizing
particle size, charge and PEGylation degree instead of adding targeting
moieties to the vehicle surface [44,51,52].
The road towards e"ective vaccines targeting the lymph nodes re-
mains long. Even when a vaccine is created that shows good uptake by
APCs and retention in lymph nodes, it will not necessarily elicit strong
adaptive immunity [53]. This may be because the vehicles do not enter
the desired lymph node region, do not release their cargo or fail to
interact with and activate the appropriate cells within lymph nodes.
Therefore, e"orts to design vaccine vehicles should focus on systems
that release the vaccine to desired regions and cell types within the
lymph node.
For ensuring adequate antigen-speci$c immunity, ensuring targeted
delivery of adjuvants to lymph nodes is equally important, if not more
so, than targeted delivery of antigens to lymph nodes. Targeted delivery
of adjuvant to lymph nodes is also important for avoiding systemic
toxicity. Adjuvants that enter the systemic circulation usually induce
unacceptable systemic in#ammation [47,54]. This argues for delivering
adjuvant and antigen together; indeed, administering adjuvant sepa-
rately after antigen leads to similar immunostimulatory e"ects as ad-
ministering antigen alone [55]. In contrast, co-localizing antigen and
adjuvant on DCs enhances the adaptive immune response [56,57].
Delivering antigen and adjuvant physically co-localized in the same
vehicle is likely preferable to co-administration of antigen and adjuvant
as separate formulations; the latter case often requires high adjuvant
doses in order to ensure that at least some APCs that have internalized
antigen are also stimulated by adjuvant. With higher adjuvant doses
comes higher risk of systemic toxicity [57,58].
5. Delivery of vaccine vehicles to tumor-draining lymph nodes
Tumor-draining lymph nodes (TDLNs) lie immediately downstream
of tumors and are the $rst sites of metastasis in many cancers. The
presence of a nearby tumor can trigger numerous changes in TDLNs,
including lymphangiogenesis, expansion of immunosuppressive cells,
Fig. 2. Design dilemma: vehicle characteristics that pro-
mote e!cient vehicle uptake by APCs often inhibit transfer
from the interstitium to lymph nodes. Small vehicles
(< 100 nm) with a negatively charged surface move more
e!ciently from the interstitium to lymphatic capillaries.
Conversely, large and positively charged vehicles are more
e!ciently phagocytosed by DCs. Denser PEGylation favors
vehicle delivery to lymph nodes but inhibits their uptake by
DCs.




mechanisms for vaccine design, Liu et al. have shown that TAAs and CpG conjugated 
to albumin-binding lipid tails generated a 30-fold increase in T cell response and 
reduced tumor growth in both TC-1 and B16F10 tumor models, compared with free 
mixtures of TAAs and CpG53. Other groups have adopted related albumin-hitchhiking 
strategies for delivery of chemotherapeutics and antigen/adjuvant combinations. In 
particular, an Evans blue analog that binds to albumin for effective LN draining has 
been reported54. This analog, termed AlbiVax, tethered to antigens or CpG readily binds 
to albumin upon injection, allowing for systemic delivery of antigens and adjuvants 
(Figure 1-7)54. Using PET imaging and Cu64-labeled Adpgk neoantigen in the MC38 
model, the authors showed that AlbiVax exhibited > 40-fold greater accumulation in LNs 
as compared to soluble peptide vaccination. Vaccination with AlbiVax-Adpgk plus CpG 
significantly increased the number of Adpgk-specific CD8+ T cells in peripheral blood, 
slowed tumor growth, and protected animals against tumor re-challenge. Combination 
immunotherapy with AlbiVax-Adpgk plus anti-PD-1 therapy further improved therapeutic 
efficacy54. As albumin-bound drug conjugates are already FDA-approved for cancer 
treatment55, albumin-mediated vaccine delivery may offer a promising clinical pathway 
for personalized cancer immunotherapy. Yet, autoimmunity against albumin or albumin-
producing hepatocytes as well as off-target toxicity of albumin-hitchhiking therapeutics 




Figure 1-7. Schematic of AlbiVax hypothesis on therapeutic efficacy against tumors. MEB = mimic of Evans blue. 
Figure taken from 54 
Self-assembled DNA-RNA nanocapsules, termed iDR-NCs, have also been 
developed for delivery of neoantigen peptides. iDR-NCs were composed of CpG for 
immune activation, Stat3 shRNA for reversing immunosuppression, and PEG-grafted 
polypeptides for delivery of neoantigen peptides. After confirming effective 
internalization of iDR-NCs by bone-marrow-derived dendritic cells (BMDCs), the authors 
validated synergistic immune-activation of DCs treated with iDR-NCs compared with 
CpG-containing larger parent particles or CpG alone. In mice, iDR-NCs loaded with 
MC38 neoantigen Adpgk peptide elicited 8-fold greater level of Adpgk-specific CD8+ T 
cell responses and exerted stronger anti-tumor efficacy as compared to the soluble 
The past decade has witnessed remarkable advances incancer immunotherapy, including immune checkpointinhibitors1. However, only limited patient populations
respond to single immune checkpoint inhibitors, and although
combining multiple biologic checkpoint inhibitors increases
response rates, it also elevates toxicity. Vaccines exploit syner-
gistic signaling pathways for combination cancer immunother-
apy. Despite the tremendous potential of subunit vaccines for
cancer immunotherapy, their clinical outcome thus far has been
suboptimal, largely due to inef!cient co-delivery of adjuvants and
Ags to secondary lymphoid organs, such as LNs where immune
responses of lymphocytes are coordinated, leading to weak
immunostimulation and immune tolerance2,3. Although tumor-
speci!c neoantigens are promising for personalized immu-
notherapy4–9, there remains a lack of a general technology to
deliver heterogenous peptide neoantigens ef!ciently. As a clinical
benchmark, subunit Ags are administered in depot-forming
water-in-oil emulsions (e.g., IFA) of CpG oligodeoxynucleotide, a
Toll-like receptor 9 (TLR9) agonist, and T helper 1 enhancer10,11.
Despite sustainable vaccine release from the depot and improved
Ag immunogenicity, IFA has limited clinical ef!cacy. Indeed, IFA






















































Fig. 1 Schematic of albumin/AlbiVax nanocomplexes for ef!cient vaccine delivery and combination cancer immunotherapy. a Upper: structure of HSA
(PDB ID: 2BXH) and chemical structure of MEB; lower: schematic structure of albumin/MEB nanocomplexes (left) and 3D molecular structure predicted by
molecular docking (right). Sticks represent MEB and the amino acid residues in the binding site I of HSA. Green dashed lines represent hydrogen bonds
between MEB and amino acids. b Working mechanism of albumin/AlbiVax nanocomplexes as potent T cell vaccines. Left box: modular structures of
AlbiCpG and albumin-binding Ag (AlbiAg). AlbiCpG were engineered by site speci!cally conjugating MEB and thiol-modi!ed CpG, with hexaethyloxy-
glycol (HEG) as tunable linkers; AlbiAg was synthesized by conjugating MEB and cysteine-modi!ed Ags, including TAA and tumor-speci!c neoantigen
discovered via exome sequencing. Left lower: locally administered AlbiVax binds to endogenous albumin and assembles into albumin/AlbiVax
nanocomplexes, which were ef!ciently delivered to LNs due to lymphatic drainage and prolonged retention in LNs. Right: harnessing the endocytosis
pathway of albumin, albumin/AlbiCpG and albumin/AlbiAg nanocomplexes were co-delivered into APCs and activated APCs for antigen cross
presentation and clonal expansion of antigen-speci!c CD8+ CTLs, thereby eliciting robust and durable antitumor immunity. While albumin/AlbiVax
nanocomplexes upregulated the expression of PD-1 on these CD8+ CTLs, combination of albumin/AlbiVax nanocomplexes with anti-PD-1 dramatically
enhanced immunotherapeutic ef!cacy in established primary and metastatic tumors. The pharmacological behaviors of albumin/AlbiVax nanocomplexes
were studied by quantitative PET imaging, light sheet "uorescence microscopy in whole cleared tissue, and super-resolution imaging in single APCs
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02191-y
2 NATURE COMMUNICATIONS | 8:  1954  |DOI: 10.1038/s41467-017-02191-y |www.nature.com/naturecommunications
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Adpgk + CpG group56. In an alternative approach, synthetic polymeric (PC7A) particles 
with an intrinsic ability to activate the stimulator of interferon genes pathway have been 
employed for induction of T cell responses against neoantigens57. PC7A nanoparticles’ 
small size of ~29 nm facilitated effective lymphatic drainage of antigen and subsequent 
cellular uptake, cross-presentation, and DC activation. After demonstrating PC7A 
nanoparticle efficacy in the B16 model of melanoma expressing ovalbumin (OVA), the 
authors have shown potent anti-tumor effect of PC7A nanoparticles delivering a cocktail 
of TAAs and neoantigens in murine models of MC38 colon carcinoma and B16F10 
melanoma57. Recently, mixtures of mesoporous silica microrod scaffolds (MSRs) each 
separately adsorbed with CpG, GM-CSF, or PEI plus antigens have been used for 
vaccination58. Including the PEI-adsorbed MSRs in the mixture significantly increased 
the expression of MHC-II and CD86 in BMDCs and production of IL-6 and TNF-alpha in 
vitro. Subcutaneous administration of MSR-PEI-OVA outperformed MSR-OVA in terms 
of increasing antigen-specific CD8+ T cells, IFN-γ production, and the effector-to-
regulatory T cell ratio. Vaccination with mixtures of MSR-CpG, MSR-GM-CSF, and 
MSR-PEI-neoantigens reduced the number of lung metastases in the model of B16F10 
and CT26 and exerted anti-tumor efficacy in synergy with anti-CTLA-4 IgG therapy58.  
Taken together, these innovative nanovaccines have yielded exciting proof-of-
concept results for personalized vaccination based on neoantigen peptides. It is notable 
that nanovaccines’ performances were further improved when combined with immune 
checkpoint blockade therapy, highlighting the importance of addressing 
immunosuppression in the tumor microenvironment for effective cancer vaccination 
(Figure 1-8). Moreover, the biomaterials used for these nanovaccines mediated 
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reduction of off-target toxicities and non-specific immune responses either by improving 
biotransport of cargo molecules or incorporation of targeting modalities. Toward the goal 
of making personalized nanovaccines a reality, the remaining engineering challenges 
include how to promote controlled release of immunomodulatory agents to enhance T 
cell infiltration into tumors post vaccination and to sustain functionality of T cells within 
the immunosuppressive tumor microenvironment. It is also necessary to examine and 
validate LN-draining and APC-targeted delivery of nanovaccines in large animals, as 
most studies in the field have been performed in murine models; stability of 
nanomaterials and LN-draining patterns may be entirely different in humans, compared 
with small murine models.  In addition, it is important to streamline GMP-manufacturing 
of personalized vaccine nanoparticles for robust adaptability to each patient’s 
neoantigens and to establish quality control measures for neoantigens with diverse 
physicochemical properties.  
 
Figure 1-8. Diagram of complex immunosuppressive tumor microenvironment (left) and its inhibition of normal 
immune activity (right). Figure taken from 37. 59 
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1.1.3. Image-guided theranostics for combination immunotherapy 
It remains challenging to target nanoparticles to specific tissues and promote their 
tissue permeation. This poses significant obstacles, especially for applications in 
immunomodulation because organ inflammation and tissue damage due to drug 
accumulation in off-target sites can lead to unintended acute or chronic immune 
responses. Biomaterial-based image-guided methods, including magnetic resonance 
imaging (MRI) and ultrasound (US), may address these issues by precisely controlling 
the timing and location of drug release60-65, potentially limiting off-target toxicity observed 
with combination immunotherapies. In addition, image-guided delivery technologies may 
enhance cell permeability and nanoparticle uptake, allowing for better characterization of 
the tumor microenvironment during and after immunotherapy. Overall, recent innovations 
and advances in image-guided theranostics for cancer treatment can be directly adapted 
to combination immunotherapy and may lead to new biomaterial-based treatment options 
tailored for each cancer patient, opening doors for personalized diagnostics and 
therapeutics.  
For MRI applications, superparamagnetic iron oxide nanoparticles (SPIONs) have 
been thoroughly investigated as theranostic nanomaterials. SPIONs can be formulated in 
a variety of sizes and functionalized with different therapeutic moieties using simple 
chemistry. Several groups have reported the use of SPIONs for early tumor diagnosis 
and perfusion66,67, treatment by thermal ablation68-70, and magnetic guidance of 
therapeutic entities71-73. Importantly, SPIONs and their modified counterparts are 
generally biocompatible and readily metabolized to iron ions and oxygen molecules. 
SPIONs decorated with single-chain CD3 antibodies and carrying immunosuppressive 
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genes have been developed for selective transfection of T cells, leading to significantly 
downregulated cytokine production and proliferation60. Administration of heat shock 
protein 70-decorated SPIONs carrying C6 glioma antigens have been reported to target 
DCs and generate anti-tumor T cells, thus inhibiting tumor growth and extending survival 
of C6 glioma-bearing rats (Figure 1-9) 74. These two studies have shown the potential of 
SPION-based theranostics for individualized combination immunotherapy.  
 
Figure 1-9. Theoretical anti-tumor mechanisms of SPIONs decorated with Heat shock protein 70 (Hsp70, nucleotide-
binding domains (NBDs) and substrate-binding domains (SBDs) shown) bound to tumor antigen peptides. Figure 
taken from 74 
Ultrasound can be applied to a target site in a focused manner with the use of 
contrast agents to deliver drugs to specific tissues. This could enhance the permeability 
of tissues for increased drug delivery and also for thermal ablation of tumor tissues while 
reducing non-specific accumulation of therapeutics. Microbubbles have been used as 
cells (APCs), especially dendritic cells (DCs) for an ef!cient induction of
antigen-speci!c T cells responses. To enhance the antigen delivery to
DCs we developed SPIONs which were conjugated to Hsp70 protein
that is known for its capacity to bind antigenic peptides [27,28]. The
synthesized Hsp70–SPIONs had the properties of MR negative contrast
agents without direct cytotoxic activity (Fig. 1). To assess the biological
activity of Hsp70 attached to the surface of SPIONs we could demon-
strate for the !rst time ATPase activity of its NBD using 31P NMR
spectroscopymethod. The substrate-binding activity of Hsp70 is depen-
dent on nucleotide hydrolysis and nucleotide exchange [29,30]. Thus
Hsp70 is regulated through the intramolecular allosteric mechanism
where the bound nucleotide state (ADP or ATP) at one site on the mol-
ecule determines the af!nity for the substrate in SBD [31]. According to
the obtained data we could show that the ATPase activity of NBD is de-
pendent on a constant fast turnover of the ATP/ADP in the NBD cleft
without strong binding of nucleotides in NBD with subsequent confor-
mational changes. In favor of this model are the data from Revington
et al. who demonstrated with the help of NMR measurements the lim-
ited structural difference between NBD with ADP–Pi or ATP states
[32]. It is important to note that an ef!cient ATPase activity of the
Hsp70–SPIONs is only observed if all components (i.e., ATP, ADP,
Mg2+ and substrate peptide) are available. In subsequent in vitro tests
using the hydrophobic BP3 peptide as a substrate we demonstrated
that Hsp70–SPIONs could bind peptides and deliver them to DCs
(Fig. 2, 3). Intriguingly, when Hsp70–SPIONs were pre-incubated with
cmHsp70.1 antibody a reduced incorporation of conjugates into DCs
was observed (Fig. 3B). Presumably, Hsp70 on SPIONS not only cargo
the antigenic peptides but also interact with receptors on DCs which
are responsible for an improved internalization of nanoparticles. Previ-
ously several surface receptors for Hsp70were described on theDCs, in-
cluding LRP/CD91, CD40, TLR2, TLR4, and LOX-1 receptors [33]. The
immunological activity of Hsp70–SPIONs to cargo peptides into DCs
was further proven in various tumor cell lines when Hsp70-conjugates
pulsed with cell lysate signi!cantly enhanced the cytolytic activity of T
lymphocytes (Fig. 4). Co-incubation of DCs with Hsp70–SPIONs and
lysate could dramatically increase the CTL activity towards tumor cells.
In vivo application of the Hsp70–SPIONs for delivery of tumor anti-
gens into DCs proved to be therapeutically bene!cial. A nearly 2-fold in-
crease in overall survival of the tumor-bearing animals could be
observed in comparison to the control group (Fig. 5C). The prolongation
of the overall survival of animals to 55.2 ± 11.0 days after treatment
withHsp70–SPIONswasmuchhigher than that achieved following con-
tinuous intratumoral injection of free Hsp70 (38.8 ± 5.4 days) via the
Alzet® osmotic pump system [8] and other Hsp70-based anti-tumor
therapies [34,35]. Presumably, DCs take up Hsp70–SPIONs together
with tumor peptides, process and load these peptides onto MHC class
I and II molecules (Fig. 6).
DCs then migrate to secondary lymphoid organs and present their
antigens to CD4+ and CD8+ T lymphocytes to initiate antigen-
speci!c anti-tumor immunity. In experimental animals treated with
Hsp70–SPIONs and tumor peptides we observed a dramatic boosting
of anti-tumor immunity, as shown by IFN! ELSIPOT assay (Fig. 5F). En-
hancement of immune response also corresponded to an increased in!l-
tration of CD45RO+, CD8+ T cells and Ly-6c + cells (NK-cells) into
tumor tissue (Fig. 5D). Previously numerous studies suggested that
tumor-in!ltrating CD45RO+ cells are associated with a favorable prog-
nosis [36–38]. Though there was a signi!cant delay of tumor progres-
sion animals eventually succumbed to the disease. This partly could be
explained by the concept of cancer immunoediting when the surviving
tumor variants following immunotherapy acquire insensitivity to im-
munologic detection and/or elimination through genetic or epigenetic
changes [39].
Application of magnetic nanoparticles as a carrier for Hsp70 with
tumor peptides signi!cantly enhanced the immune response. Previous-
ly several studies demonstrated the ef!cacy of immunization with
nanoparticles of various formulations including virus-like nanoparticles
expressing RSV glycoproteins, erythrocyte membrane-enveloped
poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles for antigenic
Fig. 6. Schematic representation of antigenic peptides delivery by Hsp70–SPIONs into dendritic cells.
338 M.A. Shevtsov et al. / Journal of Controlled Release 220 (2015) 329–340
 
 19 
ultrasound contrast agents (UCAs) for decades in clinical diagnostics due to their ability 
to backscatter sound waves with which they come in contact. In the last decade, 
microbubbles have attracted considerable interest as drug delivery vehicles due to their 
ability to produce enough shear force during stable oscillations or acoustic collapse to 
permeabilize cell membranes75. Microbubbles, like SPIONs, can be functionalized with a 
variety of therapeutic molecules. A few groups have shown successful tumor regression 
using ultrasound-mediated delivery of chemotherapeutics to different solid tumors76-79. 
Others have applied this technology for personalized cancer immunotherapy through the 
application of ultrasound at the individual’s specific tumor site after systemic 
administration of immunomodulatory agents to maximize delivery to the target site. This 
strategy has been successfully applied in a number of tumor models, including a rat 
glioma model using soluble IL-12 (Figure 1-10); a mouse hepatoma model using 
thymidine kinase; and other murine tumor models, such as lymphoma, neuroblastoma, 




Figure 1-10. Schematic of ultrasound-mediated blood-brain barrier opening following i.v. administration of ultrasound 
contrast agents (microbubbles) and therapeutic entities (IL-12) with the application of focused ultrasound (FUS) 
energy. Figure taken from  78 
1.2. Synthetic high density lipoprotein (sHDL) nanoparticles for neoantigen delivery 
1.2.1. Composition and physicochemical advantages of sHDL 
sHDL nanodiscs are particularly suited for neoantigen vaccination due to their small 
size (~ 10 nm in diameter), stability, and biocompatibility. In addition, whereas large-
scale manufacturability and clinical safety are major hurdles for clinical translation of 
nanomedicines in general83, the sHDL vaccine technology builds on cGMP-
manufacturability and clinical safety previously demonstrated in clinical trials for 
cardiovascular applications84. sHDL nanodiscs are simply composed of phospholipids 
and Apolipoprotein-A1 (Apo-A1) mimetic peptides, which spontaneously form nanodiscs 
upon hydration in aqueous buffer. These nanodiscs are representative of pre-b HDL, 




All animal experiments were approved by the animal
committee (Chang-Gung University, Taoyuan, Taiwan)
and adhered to the experimental animal care guidelines.
Pathogen-free male Sprague–Dawley rats (200–225 g)
were purchased from the National Laboratory Animal
Center (Taipei, Taiwan). C6 glioma cells were harvested
by means of trypsi ization and cultur d at a concentra-
tion of 1 ! 105 cells/mL for implantation. A total of 5 !L
of C-6 glioma cell suspension were injected at a depth of
4.5 mm from the brain surface. The injection was per-
formed over a 10-min period, and the needle was with-
drawn over another 2 min.
Control rats were injected with C6 glioma cells, but
received sham ultrasound procedure with no energy. A
second group of rats was subjected to focused ultra-
sound at the selected pressure level (5 W) at day 11, day
13, and day 15 after tumor implantation. A third group
of rats received a single dose per day for 5 days of IL-12
(0.3 !g/kg/day) via intraperitoneal injection (IP) from
day 11 to day 15 after they were injected with the tumor
cells. A fourth group of rats received 5-days IL-12
(0.3 !g/kg/day) IP combined with 3 times of 5-w focused
ultrasound on day 11, 13, and 15. There are 12 rats in
each group for flow cytometry, at least 12 rats in each
group for efficacy and magnetic resonance image (MRI)
study, and 3 rats in each group for immunohistochemi-
cal (IHC) study. Ten days after implantation, tumor sizes
were measured using 7 Tesla MRI scanner. Animals
were assessed longitudinally by MRI at one-week inter-
vals up to day 38 to determine tumor size. The animals
were anesthetized with 2% isoflurane throughout the
MRI imaging process, placed in an acrylic holder and
positioned in the center of the magnet. Tumor size was
quantified using T2-weighted images with the following
parameters: TR/TE = 2500 ms/68 ms, matrix size = 176 !
256, FOV = 31 ! 35 mm (resolution = 0.18 ! 0.14 mm).
The treatment and evaluation timelines are shown in
Figure 2.
Focused ultrasound exposure
Animals were anesthetized with a mixture of oxygen
(with flow rate of 0.8 L/min) and 2% vaporized isoflur-
ane using an anesthesia vaporizer. The top of the cra-
nium was shaved with clippers, and a PE-10 catheter
was inserted into the tail vein for injections. The animal
was placed directly under an acrylic water tank with its
head attached tightly to the thin-film, 4 ! 4 cm2 window
at the bottom of the tank. A focused ultrasound trans-
ducer (Sonic Concepts, Seattle, WA, USA; operating fre-
quency = 0.5 MHz, active element diameter = 64 mm,
radius curvature = 55 mm) driven by an arbitrary func-
tion generator (33220A, Agilent, Palo Alto, CA, USA)
with a radio-frequency power amplifier (150A100B,
Amplifier Research, Souderton, PA, USA) for RF signal
amplification and a power meter (Model-4421, Bird,
USA) for electrical power sensing was used. FUS expos-
ure was 5 or 20 Watt (W) in electric power, equivalent
to measured acoustic negative-peak pressures of 0.36 –
0.7 MPa. Before FUS exposure, a 0.1 mL/kg bolus of
Figure 1 Schematic of FUS-induced BBB opening to enhance IL-12 delivery in brain glioma treatment.
Chen et al. Journal of Translational Medicine  (2015) 13:93 Page 3 of 12
 
 21 
the lipid-poor HDL that readily accumulates other phospholipids and cholesterol that 
have been effluxed by cells into the blood85. As such, the lipid bilayer allows for facile 
loading of small amounts of lipid-conjugated antigen peptides and adjuvants without 
increasing the size of the nanodiscs significantly. Furthermore, sHDL nanodiscs can 
readily bind to lipoprotein cell receptors such as scavenger receptor class B member 1 
(SR-B1), which is overexpressed on APCs, allowing for targeted delivery of nanodiscs 
to APCs in LNs86-89.  
1.2.2. Prior demonstration of neoantigen delivery by sHDL 
Earlier studies conducted in our lab evaluated the immunotherapeutic potential of 
murine colon carcinoma MC38 neoantigen Adpgk in conjunction with toll-like receptor 9 
(TLR9) agonist CpG oligonucleotide. Mice vaccinated with Adpgk/CpG-sHDL nanodiscs 
elicited ~47-fold greater frequency of Adpgk-specific CD8+ T cells, compared with 
soluble Adpgk and CpG16. When neoantigen nanodisc vaccination was combined with 
immune checkpoint blockade (anti-PD-1 IgG therapy), more than 85% of animals 
demonstrated tumor eradication in the murine models of MC38 colon adenocarcinoma 
and B16F10 melanoma. Interestingly, in the murine model of B16F10 melanoma, 
vaccination with a cocktail of nanodiscs carrying a TAA, TRP2, and two neoantigens, 
M27 and M30, had a noticeable advantage over vaccination with TRP2 or two 
neoantigens alone, suggesting the benefits of vaccines targeted against a large set of 
TAAs and neoantigens16. In addition, compared with intramuscular route, subcutaneous 
administration of nanodiscs enhanced LN-targeted delivery of antigens and adjuvants, 
leading to an 8-fold increase in the frequency of neoantigen-specific T cells and 
elimination of large established B16F10 tumors90. It remains to be seen whether sHDL 
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vaccines personalized with neoantigens can achieve significant patient survival benefit 
in the clinic16,91,92. In this dissertation, sHDL nanodiscs were used as carriers for 
neoantigens derived from GL261 murine GBM tumors to determine the therapeutic 
potential of the nanovaccine in such a non-targetable cancer (Chapter 2). 
1.2.3. Limitations of sHDL as a drug delivery vehicle 
Because sHDL is formulated using water-insoluble phospholipids and water-soluble 
peptides, synthesis of the nanodiscs up until this point has required the use of both 
organic solvents to create homogeneous mixtures and lyophilization to remove organic 
solvents from final reaction products. While organic solvent use and removal is common 
in drug manufacturing, the scale at which these processes would have to occur has not 
yet been tested for the antigen delivery application. Material loss upon lyophilization and 
reconstitution would need to be considered in addition to the individualized pH 
adjustments performed for each antigen peptide formulation. Moreover, the 
lyophilization process itself can be ridden with inconsistencies leading to instability of 
the active pharmaceutical ingredients—in this case, peptides and lipids—that could 
significantly affect therapeutic performance93. The complex process of formulating the 
neoantigen-loaded sHDLs described in Chapter 2 is not entirely compatible with large-
scale manufacturing processes. Fortunately, the work described in Chapter 3 
potentiates a solution to these limitations.  
1.3. Current treatment approaches for GBM 
Brain cancers continue to be some of the most deadly and untreatable malignancies 
around the world, responsible for nearly 17,000 deaths and are diagnosed in over 
75,000 people annually. They are the most common forms of childhood cancer with 
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leukemia being the second most common.  Though there are many histologically unique 
types, brain cancers remain difficult to treat given the delicate complexity of the host 
tissue 94. Primary tumors, those that arise in the brain and are not results of metastases, 
are categorized broadly into meningiomas, gliomas, pituitary tumors, and nerve sheath 
tumors. These tumors are classified by their original location in the brain but will likely 
invade neighboring brain tissue with time. Astrocytomas and glioblastomas, both 
advanced types of gliomas, cannot be fully removed by resection due to their anaplastic 
nature. Radiation typically follows surgical resection of the tumor to rid the brain of any 
remaining tumor cells and is also used to treat tumors that cannot be resected. 
However, the major concern with radiation is that it is quite harmful to normal brain cells 
and cannot be too specifically focused on the tumor alone. The next level of treatment 
for brain cancers is chemotherapy, which also has a major obstacle to overcome: the 
blood-brain barrier (BBB). Most drugs cannot cross the BBB or are effluxed by brain 
transporters and thus exert no therapeutic effect on the brain tumor but produce 
unwanted side effects due to systemic administration. Physicians can sometimes 
circumvent this issue by injecting drug directly into the patient’s cerebrospinal fluid 
(CSF) with a catheter system, but such an approach defeats the purpose of 
chemotherapy being a noninvasive method of treatment 95. Increased interest in 
targeted therapies has led to the development of technologies that can overcome some 
of these obstacles, but most are either invasive or elicit strong and unfavorable off-
target effects. Thus, there remains a need for a minimally invasive yet effective 
treatment for brain cancers that is limited in action to the tumor site itself.  
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Gliadel, an FDA-approved wafer implant releasing the anti-neoplastic alkylating 
agent Carmustine, virtually eliminates treatment-related side effects because it is placed 
directly into the tumor site. Gliadel was mainly designed for high-grade gliomas that 
cannot be rid of with surgery and radiation alone. Although the implant is far more tumor 
site-specific than any other approach, the surgery required for placement of the wafers 
can result in a variety of complications such as hydrocephalus and brain edema. In fact, 
physicians predict that almost one out of every four patients receiving the implant will 
experience brain edemas 96. In 2009, bevacizumab, an antibody against vascular 
endothelial growth factor (VEGF) 97, was approved by the FDA for recurrent GBM 
treatment after having been on the market for several years to treat colorectal, lung, 
breast, and renal cancers. Bevacizumab showed marked VEGF inhibition in phase 2 
clinical trials as evidenced by significant reductions in glucose uptake and cerebral 
edema but has ultimately provided no survival benefit to patients. Thus, there remains a 
need for a noninvasive, targeted therapy that will eliminate brain tumors and improve 
brain cancer patient survival outcomes.  
Immunotherapy is an increasingly attractive treatment option for brain cancers 
because it has the potential to reverse the immunosuppressive tumor 
microenvironment, target tumor antigens and neoantigens, and maintain a long-lasting 
anti-tumor response. Enhanced tumor cell expression of programmed death receptor 1 
(PD-1) ligands has been shown to increase T cell apoptosis and to suppress anti-tumor 
immunological efforts in multiple cancers, including the brain 6,98,99. Anti-PD-1 antibodies 
effectively block the induction of T cell death by PD-1 ligands to preserve T cell activity, 
promoting the anti-tumor immune response. Though proven effective in a significant 
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number of patient cases, the major downfall of these immune checkpoint inhibitors is 
that they rely on specific cancer cell phenotypes and protein expression profiles in 
patients with highly heterogenous tumors, including brain cancers. 
Thus, the field has shifted focus toward more tumor-specific approaches to 
immunotherapy. Tumor lysates contain tumor antigens and neoantigens, which can be 
harnessed to induce a tumor-targeted immune response. Currently, a Phase 3 clinical 
trial testing DCVax-L, a tumor lysate-pulsed dendritic cell vaccine, against newly 
diagnosed GBM is underway. DCVax-L has shown promising preclinical and early 
clinical results, with 50% of treated patients surviving to 32 months as compared to a 
16-month 50% survival rate for untreated patients without any dose-limiting toxicities100. 
The vaccine, which is administered intradermally, has also demonstrated significantly 
enhanced tumor infiltration of CD8+ T cells (Figure 1-11), increasing the probability of 
antigen-specific cytotoxic T cell-mediated tumor cell killing 101. However, the 
manufacturing of DCVax-L requires extensive regulation with respect to culturing the 
patients’ cells for re-injection and preparing tumor lysate, all of which is time-consuming 
and time-sensitive. Additionally, the tumor-lysate pulsed cells are not guaranteed to 
express potent antigens due to the variety of components in tumor lysates.  
In a more specific approach, Celldex Therapeutics took advantage of the common 
yet heterogeneous overexpression of EGFRvIII peptide on GBM cells and formulated a 
tumor-specific antigen vaccine, rindopepimut, which made it into a phase III clinical trial 
comprised of patients with newly diagnosed EGFRvIII-positive glioblastoma who had 
undergone tumor resection. On March 7, 2016, Celldex announced that it was halting 
this phase III trial based on findings from an interim data analysis that showed patients 
 
 26 
receiving rindopepimut were unlikely to have an improvement in overall survival 
compared with patients in the control arm102. These lackluster results could be due, in 
part, to the tumor heterogeneity and also to inefficient peptide delivery to the tumor.  
 
 
Figure 1-11. Proposed mechanisms of T cell migration across the BBB. Figure taken from 103. 
Neoantigens have such a large therapeutic advantage over shared antigens and 
immune checkpoint antibodies because of their targetability and potential for patient 
personalization. Neoantigen delivery to dendritic cells can induce highly specific anti-
tumor responses through the cross-presentation of neoantigens to cytotoxic CD8+ T 
cells without any normal cell killing. Interestingly, in 2016, a group out of Washington 
University in St. Louis published their discovery of several unique neoantigens in GL261 
and SMA-560 murine glioblastoma tumors. The investigators used whole exome and 
RNA sequencing to identify the initial candidate neoepitopes and further narrowed the 
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candidate pool using enzyme-linked immunosorbent spot (ELISPOT) and tetramer 
analyses. The most promising results from this study were the detectable frequencies of 
neoantigen-specific T cells in both brain tumors and the draining cervical lymph nodes 
in tumor-bearing mice that had not been vaccinated or treated with any other agents104. 
Unfortunately, effective lymphatic delivery methods for neoantigens do not currently 
exist, and there remains a need for a simple and efficient delivery system for 
neoantigens to bring a highly effective immunotherapy for GBM to market. In this 
dissertation, a potential solution for this need was developed using the GL261 
neoantigen sequences identified in 2016 and will be described thoroughly in Chapter 2.  
1.4. Current treatment approaches for Colon carcinoma 
Colon carcinomas are a subset of colorectal cancers, the third most common cancer 
diagnosed across both sexes. Colon carcinomas themselves comprise over two-thirds 
of all colorectal cancers with an overall 5-year survival rate of 64%, which rapidly 
decreases to 14% when the cancer becomes distant or metastatic, usually progressing 
into the liver. Depending on the stage of colon carcinoma at diagnosis, patients can 
undergo surgery to attempt tumor resection. These patients are still given 
chemotherapy following surgery to eliminate any tumor cells that may have been left 
behind. Patients who do not have the option of surgery usually receive chemotherapy 
as the first line of therapy with one or a combination of the following drugs: thymidylate 
synthase inhibitor 5-fluorouracil (5-FU) or its prodrug capecitabine, topoisomerase I 
inhibitor irinotecan, DNA intercalator oxaliplatin, or a combination drug composed of 
DNA intercalator trifluridine plus thymidine phosphorylase inhibitor tipiracil. As with most 
cancers, colon carcinomas do not always respond to chemotherapies, and patients 
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often discontinue treatment due to unmanageable side effects. Fortunately, regional 
chemotherapy can be given to patients with localized cancer through the hepatic artery, 
but many patients do not have this luxury. Thus, targeted therapies and 
immunotherapies have been developed to aid chemotherapy.  
Approved targeted therapies for colon carcinoma are limited to VEGF inhibitors, 
including bevacizumab used in treatment regimens for aforementioned GBM patients, 
epidermal growth factor receptor (EGFR) inhibitors, and kinase inhibitors. All of these 
inhibitors aim to prevent new blood vessel formation around the tumor or to interrupt 
tumor cell proliferation so that tumor growth can be slowed. Because they do not 
directly induce tumor cell killing, they are usually given in combination with 
chemotherapy for maximum therapeutic effect. Immunotherapies also induce indirect 
tumor cell killing; anti-CTLA-4 and anti-PD-1 prevent T cell death, allowing for increased 
T cell activation, tumor recognition, and tumor cell killing105. Unfortunately, these 
targeted therapies and immunotherapies are associated with several adverse events 
due to their systemic or oral administration.  
To overcome the limitations of current colon carcinoma therapies, much research is 
focusing on developing therapeutic vaccines similar to those discussed for GBM. 
Shared tumor antigen peptide vaccines targeting commonly overexpressed proteins in 
cancer such as EGFR and Mucin-1 have been developed and studied in combination 
with chemotherapy but have shown no overall survival benefit when compared to 
chemotherapy alone106. In 2014, Hazama et al. reported the use of a five peptide 
cocktail comprised of three tumor-associated antigens restricted by HLA-A*2402, a 
human leukocyte antigen (HLA) allele expressed by a significant proportion of 
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Southeast Asian people, and two VEGF antigens in combination with oxaliplatin 
chemotherapy as a potential frontline therapy for Japanese colorectal cancer patients in 
a phase II study. The peptide cocktail was mixed with Freund’s adjuvant for 
administration. Unfortunately, no differences in survival benefits were observed between 
patients with and without HLA-A*2402 expression107. Around the same time, Okuno et 
al. reported the use of a seven-peptide cocktail comprised of five tumor-associated 
antigens restricted by HLA-A*2402 and two VEGF antigens in combination with tegafur-
uracil plus leucovorin (UFT/LV) chemotherapy in Japanese colorectal cancer patients. 
Out of 30 patients, 15 exhibited stable disease while 3 showed partial responses to 
therapy. The investigators calculated that patients who showed positive antigen-specific 
T cell responses to all seven antigen peptides were more likely to experience a 
significant improvement in overall survival108. However, a much greater sample size is 
needed to confirm these results, and the requirement of a response to all seven 
peptides to increase survival odds is quite lofty. Neoantigen vaccination has also been 
investigated in colorectal cancer patients. Tumor-specific KRAS mutations have been 
identified and formulated into vaccines using either the peptide itself or activated 
cytotoxic T cells that recognize the mutated peptide. Both of these vaccines increased 
the immune response against neoantigens, but only the T cell vaccine resulted in 
significant disease regression109,110. A major limitation of these therapeutic strategies is 
the poor delivery system of the therapeutic entities; peptides dissolved in emulsions 
often have difficulty trafficking to the lymph nodes while vaccination of peptide-
presenting dendritic cells or peptide-recognizing T cells requires very particular, time-
consuming, and low-yield autologous cell culture. Thus, many researchers have begun 
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developing delivery systems for tumor-associated antigens and neoantigens using 
liposomes, viral vectors, and polymeric nanoparticles as well as combinatorial treatment 
regimens using a mix of chemotherapies, targeted therapies, and immunotherapies. In 
Chapter 4, a potential solution to improving treatment for colon carcinoma is described, 
encompassing a couple of the strategies aforementioned through co-delivery of 
chemotherapy and immunotherapy using sHDLs.   
1.5. Research Scope 
Thus far, this introduction has highlighted the current state of cancer immunotherapy 
and the promise of neoantigens as immunotherapeutic agents in brain and colon cancer 
treatment. Synthetic HDLs have also been discussed as clinically translatable drug 
delivery platforms given their prior demonstration as biocompatible nanoparticles in both 
cardiovascular and oncologic applications. Here, we aim to harness the excitement 
surrounding neoantigens for cancer immunotherapy and the clinical potential of sHDL 
as a drug delivery vehicle to create novel combinatorial immunotherapies for patients 
suffering from Glioblastoma multiforme and Colon adenocarcinoma.  
1.6. Thesis Overview
The overall goal of this thesis is to develop a clinically translatable and scalable 
platform for co-delivery of neoantigens or chemotherapeutic molecules and adjuvants 
directly to tumors or tumor-draining lymph nodes for site-specific treatment that is 
minimally invasive and reduces off-target side effects. To achieve this goal, we studied 
the anti-tumor effects elicited by neoantigen or chemotherapy-loaded sHDL in two 
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different tumor models and simplified the complex formulation process for neoantigen-
loaded sHDL to streamline development of personalized cancer vaccines.  
In Chapter 2, we explore the ability of murine Glioblastoma multiforme neoantigens 
co-delivered with adjuvant on sHDL nanodiscs to generate neoantigen-specific CD8+ T 
cells, slow tumor growth, and prolong overall survival in tumor-bearing mice.  We also 
incorporate immune checkpoint blockade anti-PD-L1 to treatment regimens to study 
further the anti-tumor effects of combination immunotherapy. Moreover, we evaluate the 
tumor microenvironment of mice vaccinated with neoantigen-loaded sHDL nanodiscs to 
determine whether immunosuppression within the tumor could be reversed. In all 
studies, we compare the pharmacodynamic effects of the nanovaccine with soluble 
neoantigen vaccination to test the hypothesis that neoantigen delivery by sHDL 
improves immune processing and anti-tumor immunity of neoantigen peptides.  
In Chapter 3, we aim to simplify our formulation process for neoantigen-loaded 
sHDL through chemical modification of two Colon adenocarcinoma neoantigen peptides 
using short chain PEG. We study whether the simplified PEGylated formulations retain 
the anti-tumor immunity of traditional formulations through assaying neoantigen-specific 
CD8+ T cell expansion and protection from tumor challenge. Through these studies, we 
can draw conclusions on the clinical translatability of the newly simplified neoantigen-
loaded sHDL personalized vaccine platform.  
In Chapter 4, we evaluate the therapeutic advantage of co-delivering chemo- and 
immune-therapeutic entities on sHDL nanodiscs in a murine Colon adenocarcinoma 
model.  We use in vitro assays to determine whether docetaxel-loaded sHDL is 
comparable to free docetaxel regarding tumor cell killing to justify sHDL as a drug 
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delivery vehicle. We then evaluate the anti-tumor efficacy of docetaxel-sHDL co-loaded 
with CpG oligonucleotide compared to single therapy docetaxel-sHDL to determine 
whether combination therapy with an immuno-stimulatory component augments the 
antitumor efficacy of chemotherapy alone. 
Chapter 5 summarizes the findings of all three chapters and provides suggestions 
for future studies to deepen the knowledge gained. Chapters 2 and 4 have been 




Chapter 2. Personalized vaccination against Glioblastoma 
multiforme using synthetic high-density lipoprotein nanodiscs 
 
2.1. Abstract 
Glioblastoma multiforme (GBM) continues to be the most deadly and untreatable 
brain malignancy. Cancer immunotherapy is an increasingly attractive treatment option 
for patients who have been through the trifecta of surgery, radiation, and chemotherapy 
only to experience tumor recurrence. A precise and sustainable approach to cancer 
immunotherapy is the delivery of tumor-specific antigens, also known as neoantigens 
(NeoAgs). However, efficient delivery of NeoAgs to immune activation sites remains a 
major challenge in this therapeutic approach.  
We have developed a synthetic high-density lipoprotein (sHDL) platform for 
delivery of NeoAgs. sHDL’s small size (< 15 nm) and high biocompatibility make sHDL 
an ideal candidate for lymphatic trafficking16,111. Here, we have tailored NeoAg peptide-
sHDL vaccine formulations to treat GBM. We show that vaccinating GL261 tumor-
bearing mice with sHDL nanodiscs co-loaded with GL261 NeoAg peptides and CpG (a 
Toll-like receptor 9 agonist) elicits robust NeoAg-specific T cell responses and delays 
tumor growth. We also show that anti-tumor effects were significantly enhanced when 
combined with anti-PD-L1 immune checkpoint blockade therapy.  
 
Briefly, blank sHDL nanodiscs were made using DMPC and apo-A1 mimetic 
peptide 22A16. GBM NeoAg peptides were conjugated to DOPE via PDP thiol chemistry 
and incorporated into sHDL nanodiscs by simple mixing, and cholesterol-modified CpG 
was added to GBM NeoAg peptide-sHDL. To study therapeutic effect, C57BL/6 mice 
were inoculated with GL261 cells and vaccinated once weekly via subcutaneous (s.c.) 
injection at the tail base with NeoAg peptide-sHDL/cho-CpG cocktail, NeoAg peptide + 
CpG cocktail, or PBS. anti-PD-L1 checkpoint blockade therapy was administered 
intraperitoneally (i.p.).   
We successfully formulated sHDL co-loaded with GBM NeoAgs and cholesterol-
CpG with loading efficiencies > 90% for NeoAg peptides and cholesterol-CpG. In our 
s.c. GL261 tumor model, we found that mice vaccinated with NeoAg peptide-sHDL/cho-
CpG cocktail + anti-PD-L1 exhibited significantly slowed tumor growth when compared 
to the control tumor-bearing mice administered with PBS (day 18, p < 0.01). Mice 
vaccinated with NeoAg peptide-sHDL/cho-CpG cocktail + anti-PD-L1 survived 
significantly longer than mice treated with NeoAg peptide-sHDL/cho-CpG and NeoAg 
peptide + CpG +/- anti-PD-L1 and PBS in both flank and orthotopic GL261 tumor 
models. Both PBMCs and splenocytes isolated from s.c. tumor-bearing mice and 
PBMCs isolated from orthotopic tumor-bearing mice immunized with NeoAg peptide-
sHDL/cho-CpG cocktail group exhibited stronger NeoAg-specific IFN-g responses 
compared to mice immunized with NeoAg peptide + CpG + anti-PD-L1 or PBS. 
Moreover, vaccination with NeoAg peptide-sHDL/cho-CpG cocktail + anti-PD-L1 was 
able to reverse immunosuppression within the tumor microenvironment in both s.c. and 
orthotopic GL261 models.  
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We conclude that NeoAg peptides delivered via sHDL nanodiscs elicit strong T cell 
responses against GBM NeoAgs and exhibit significant anti-tumor efficacy against 
GL261 tumors in both s.c. and orthotopic tumor models. Future work will include further 
optimization of treatment regimens for orthotopic models and in-depth analysis of tumor-
infiltrating neoantigen-specific T cells.  
2.2. Introduction 
Glioblastoma multiforme (GBM) is a devastating stage IV brain cancer that 
affects less than 5 per 100,000 people each year but has a median survival rate of only 
15 months112. Currently, the standard-of-care for patients diagnosed with GBM is limited 
to surgery, radiation, and chemotherapy. This care is likely ineffective due to failure to 
resect 100% of the tumor and inefficient delivery of chemotherapeutic drugs to the 
brain. GBM spreads quickly throughout the brain, and the blood-brain barrier is difficult 
to penetrate given the plethora of transporters policing the brain and forcing foreign 
molecules back out into the systemic circulation, leading to off-target toxicities. To 
address these issues, the controlled release implant Gliadel, launched in 1995, can be 
placed at the site of tumor resection for sustained, long-term release of Carmustine, an 
alkylating agent, into the brain to attack any residual tumor cells or recurring 
malignancy.  Unfortunately, Gliadel has not significantly improved patients’ prognoses, 
warranting a need for new therapeutic approaches. Immune checkpoint blockade has 
been employed in several types of cancer as an immunotherapy to reinvigorate the 
immunogenic response against tumor cells but has not yet been clinically approved for 
GBM. Clinical trials studying anti-PD-1 and anti-CTLA4 therapies in patients with both 
primary and recurring GBM are ongoing but have no conclusive results yet113.  
 
 36 
A more specific approach to immunotherapy is to vaccinate patients against their 
own tumor cells using tumor-specific antigens, or neoantigens. Current neoantigen 
delivery methods, such as direct injection and oil emulsions, often result in precipitation, 
accumulation, and sustained inflammation at the injection site with minimal lymphatic 
drainage and consequential tolerance and deletion of antigen-specific T cells at the 
injection site. Thus, there is a need for better delivery methods to ensure neoantigen get 
to the antigen presenting cells 56 in the lymph nodes to elicit the anti-tumor immune 
response. An ideal neoantigen vaccine system should promote stable and efficient 
transport of neoantigen peptides to APCs in lymphoid tissues while allowing co-
localized delivery of both antigens and adjuvant molecules to the same APCs without 
causing an unwanted inflammatory response. These “nanovaccines” are gaining 
momentum in cancer immunotherapy as nanoparticles with an optimal size (10-100 nm) 
for lymphatic trafficking and targeted delivery of antigens to APCs52. 
Endogenous HDL is known to be endocytosed by dendritic cells through the 
scavenger receptor-B1 (SR-B1) pathway, making the nanostructure a good candidate 
for carrying neoantigen peptides to target cells. Our lab has previously demonstrated 
that lipid-conjugated peptides can be successfully inserted into sHDL nanodiscs along 
with toll-like receptor 9 (TLR9) agonist CpG as an adjuvant and that these 
nanoformulations traffic effectively to draining lymph nodes. Here, we tailored previous 
methods for peptide loading into sHDL to newly discovered murine GBM neoantigen 
peptides in order to develop a nanoformulation for vaccinating against GBM in tumor-
bearing mice.   
 
 37 
2.3. Materials & Methods 
2.3.1. Selection of neoantigen peptides 
Neoantigen peptide sequences chosen from an immunogenomics study on 
murine glioblastoma models published in 2016 were computationally screened for 
predicted MHC reactivity using the artificial neural network (ANN) method tool before 
selection for formulation 104. Six out of ten neoantigen peptides identified in the study 
were synthesized (RS Synthesis) and screened for in vivo immunogenicity according to 
the results from predicted MHC binding affinities produced by the Immune Epitope 
Database and Analysis Resource (Table 2-1).    
2.3.2. Design of screening study  
Female C57BL/6 mice, aged 6-7 weeks, were shaved and inoculated with 1.2 x 
106 GL261 cells subcutaneously (s.c.) in the flank. On days 4 and 11 after inoculation, 
50 µg of each neoantigen peptide (n = 4) was co-administered with two strong 
adjuvants, anti-CD40 (50 µg) and toll-like receptor 3 (TLR3) agonist Polyinosine-
polycytidylic acid (polyIC) (100 µg), intraperitoneally (i.p.) to amplify the immune 
responses to highly immunogenic peptides. Anti-CD40 is an agonistic monoclonal 
antibody for CD40 present on DCs and  promotes ligation with CD40 ligand 114 on T 
cells. The interaction between CD40 and CD40L enhances DC survival, cytokine 
release, and upregulation of costimulatory receptors like CD80 and CD86 as well as 
MHC class I and II molecules to induce DC maturation. The interaction also stimulates 
CD4+ T cells themselves and can prime cytotoxic T lymphocytes via DCs114. PolyIC is 
an agonist for TLR3 present on DCs to promote immunostimulatory cytokine release. 
The top peptide candidate was also incorporated into sHDL nanodiscs to test the 
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immunogenicity of the complete nanovaccine. The formulation details are explained in 
the next section. On day 26, all mice were euthanized for spleen extraction and 
Interferon-g (IFN-g) ELISPOT analysis to evaluate and compare the immunogenicity of 
the neoantigen peptide candidates.  
2.3.3. Formulation and characterization of neoantigen peptide-loaded sHDL 
nanodiscs 
sHDL nanodiscs were prepared by dissolving 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC, NOF America Corporation) and 22A Apolipoprotein-A1 mimetic 
peptide (GenScript) in acetic acid, lyophilizing the mixture, and rehydrating the mixture 
in 10 mM sodium phosphate buffer followed by thermocycling to form ~10 nm nanodiscs 
spontaneously. The DMPC phospholipid enabled formation of a lipid bilayer while the 
22A peptide wrapped itself around the bilayer to mimic an endogenous HDL particle. 
Nanodisc size was confirmed by dynamic light scattering (DLS) analysis. For 
neoantigen peptide incorporation, the peptides were modified with a cysteine-serine-
serine sequence at the N-terminus for facile conjugation to thiol-modified lipids. Modified 
peptides were mixed with a pyridiyl disulfide-modified neutral lipid, 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine-N-[3-(2-pyridyldithio)propionate] (DOPE-PDP, Avanti 
Polar Lipids), in dimethylformamide (DMF) for 2-3 hours on an orbital shaker to form a 
lipid-peptide conjugate through thiol chemistry. The conjugate was lyophilized to remove 
DMF and rehydrated in dimethylsulfoxide (DMSO). Before adding the conjugate to the 
sHDL solution, the sHDL solution’s pH was adjusted according to the peptide’s 
predicted isoelectric point (pI) with either hydrochloric acid (HCl) or ammonium 
hydroxide (NH4OH) to ensure complete peptide solubility. The full mixture was 
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incubated on an orbital shaker at 200 rpm for 1 hour. Cholesterol-modified CpG1826 
(cho-CpG, Integrated DNA Technologies), a TLR9 agonist, was incorporated into 
peptide-loaded nanodiscs as an adjuvant by simple mixing at a DMPC:cho-CpG weight 
ratio of 50:1. All formulations were analyzed by DLS for size, by UPLC/MS and HPLC to 
confirm lipid-peptide conjugation and conjugate incorporation into nanodiscs, and by 
GPC to confirm cho-CpG loading. A Malvern Zetasizer was used for size and zeta 
potential analysis (Nanotechnicum, University of Michigan). HPLC was performed using 
a Thermo Scientific™ BioBasic™ Phenyl HPLC Column. UPLC/MS was performed 
using either an Acquity UPLC® BEH HILIC 1.7 µm 2.1 x 50 mm column or an Acquity 
UPLC® BEH300 C4 1.7 µm 2.1 x 150 mm column. GPC was performed using a TSKgel 
G3000SWxl column from Tosoh Bioscience. 
2.3.4. Treatment regimens for in vivo studies using subcutaneous GL261 tumor 
models 
For the screening study, female C57BL/6 mice, aged 6-7 weeks, were shaved 
and inoculated with 1 x 106 GL261 cells subcutaneously (s.c.) in the flank. On days 4 
and 11 after inoculation, 50 µg of each neoantigen peptide (n = 4) was co-administered 
with two strong adjuvants, anti-CD40 (50 µg) and toll-like receptor 3 (TLR3) agonist 
Polyinosine-polycytidylic acid (polyIC) (100 µg), intraperitoneally (i.p.) to amplify the 
immune responses to highly immunogenic peptides. The predicted top peptide 
candidate, AALLNKYLA, was also incorporated into sHDL nanodiscs to test the 
immunogenicity of the complete nanovaccine. On day 26, all mice were euthanized for 
spleen extraction and Interferon-g (IFN-g) ELISPOT analysis to evaluate and compare 
the immunogenicity of the neoantigen peptide candidates.  
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 For therapeutic vaccination studies, immunocompetent female C57BL/6 mice 
were inoculated with 1.2 x 106 GL261 cells s.c. in the flank. When tumors were palpable 
8 days after inoculation, mice were administered s.c. at the tail base with neoantigen 
peptide-sHDL/CpG cocktail, soluble neoantigen peptide cocktail + CpG, or PBS. Half of 
the mice received anti-PD-L1 i.p. at days 1 and 4 after vaccination. A prime-boost 
regimen was followed with vaccinations 7 days apart. Peptides were dosed at 15 µg 
each, CpG was dosed at 15 µg, and anti-PD-L1 was dosed at 100 µg (Figure 2-5). Five 
treatment groups were analyzed (n = 14), two of which represented combination 
immunotherapy regimens with checkpoint inhibitor anti-PD-L1: neoantigen peptide-
sHDL/CpG cocktail (+/-) anti-PD-L1, soluble neoantigen peptide cocktail + CpG (+/-) 
anti-PD-L1, and PBS. Anti-PD-L1 was chosen as the checkpoint blockade antibody for 
combination immunotherapy groups because PD-L1 is known to be highly expressed on 
the majority of glioblastoma cells 115. Mice were euthanized when tumors reached 1.5 
cm in diameter. Long-term survivors that exhibited complete tumor regression were 
rechallenged on the contralateral flank with 1 x 106 GL261 cells.  
2.3.5. IFN-g ELISPOT assay of splenocytes and PBMCs 
For analysis of splenocytes, mice were euthanized 15 days after the boost 
vaccination in the neoantigen screening study and 6 days after the prime vaccination for 
the therapeutic study. Spleens were excised and processed with ACK lysis buffer 
(Invitrogen) to remove red blood cells. Splenocytes were washed with PBS, 
resuspended in RPMI media (Invitrogen) + 10% FBS + 1% Penicillin/Streptomycin, and 
counted using a hemocytometer. Splenocytes were plated on a 96-well ImmunoSpot 
plate (Fisher Scientific) that was pre-coated with anti-IFN-g capture antibody at a cell 
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density of 0.5 x 106 cells per well. Neoantigen peptides were dissolved in water and 
incubated with PBMCs for 18 hours at 37°C. Culture solutions were then discarded, and 
spots were enumerated using a mouse IFN-g ELISPOT reagent kit (Fisher Scientific). 
An ImmunoSpot analyzer was used to count the number of spots per well (Cancer 
Center Immunology Core, University of Michigan).  
For analysis of PBMCs, blood was taken from the submandibular veins of mice 6 or 
7 days after each vaccination and processed with ACK lysis buffer to remove red blood 
cells. PBMCs were washed with PBS, resuspended in RPMI media (Invitrogen) + 10% 
FBS + 1% Penicillin/Streptomycin, and counted using a hemocytometer. Neoantigen 
peptides were dissolved in water and incubated with PBMCs for 18 hours at 37°C. 
Culture solutions were then discarded, and spots were enumerated using a mouse IFN-
g ELISPOT reagent kit (Fisher Scientific). An ImmunoSpot analyzer was used to count 
the number of spots per well (Cancer Center Immunology Core, University of Michigan).  
2.3.6. Tumor microenvironment analysis of GL261 tumors in s.c. GBM model 
Immunocompetent C57BL/6 mice were inoculated with 1.2 x 106 GL261 cells s.c. in 
the flank. Three treatment groups were analyzed, two of which represented combination 
immunotherapy regimens with checkpoint inhibitor anti-PD-L1: neoantigen peptide-
sHDL/CpG cocktail + anti-PD-L1 (n=4) and soluble neoantigen peptide cocktail + CpG + 
anti-PD-L1 (n=4), and PBS (n=6). Mice were vaccinated when tumor reached 7-9 mm in 
diameter so that tumors would be large enough to harvest sufficient cells at the point of 
analysis, and they were given anti-PD-L1 on days 1 and 4 after vaccination as in other 
studies outlined above. On day 8 after vaccination, mice were euthanized so that 
tumors could be harvested for fluorescence-activated cell sorting (FACS) analysis 
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(BioRad Ze5, Flow Cytometry Core, University of Michigan) (Figure 2-13). Tumors were 
digested into single cell suspensions using a cocktail of DNase I and collagenase. 
Three different panels were assessed: regulatory T cells, CD8 T cells, and dendritic 
cells. Both CD8 and dendritic cells were further analyzed for activation markers and 
phenotypes. Antibodies used for FACS analysis were rat anti-mouse CD16/32 (Fisher 
Scientific), rat anti-mouse CD8a Brilliant Violet 605 (BD Biosciences), rat anti-mouse 
CD4 Brilliant Violet 605 (BioLegend), rat anti-mouse FoxP3 PE (BD Biosciences), anti-
mouse CD279/PD-1 (BioLegend), rat anti-mouse CD107a APC (BD Biosciences), anti-
mouse CD103 APC (BioLegend), rat anti-mouse CD86 PE-Cy7 (BioLegend), anti-
mouse CD3 FITC (BioLegend), anti-mouse MHC Class II/I-A/I-E PE (ThermoFisher 
Scientific), hamster anti-mouse CD69 PE (BD Biosciences), anti-mouse CD11c FITC 
(BioLegend), and rat anti-mouse CD25 PE-Cy7 (BD Biosciences).  
2.3.7. Treatment regimens for in vivo studies using orthotopic GL261 tumor 
models 
Immunocompetent female C57BL/6 mice were stereotactically injected with 20,000 
GL261 cells into the right striatum using a 22-gauge Hamilton syringe (1 μL over 1 
minute) with the following coordinates: +1.00 mm anterior, 2.5 mm lateral, and 3.00 mm 
deep to establish brain tumors116. Three treatment groups were analyzed: neoantigen 
peptide-sHDL/CpG cocktail + anti-PD-L1, soluble neoantigen peptide cocktail + CpG + 
anti-PD-L1, and PBS. For the pilot therapeutic study, mice were vaccinated s.c. at the 
tail base with the nanodisc vaccine or free neoantigen peptides and given anti-PD-L1 
i.p. on the same day for 3 vaccinations each one week apart. For the second 
therapeutic study, mice were vaccinated s.c. at the tail base with the nanodisc vaccine 
 
 43 
or free neoantigen peptides for 4 vaccinations each one week apart and given anti-PD-
L1 i.p. on the same day as each vaccination plus 1 and 4 days after each vaccination 
for 12 total doses (Figure 2-17). Long-term survivors in the nanovaccine treatment 
group were rechallenged by inoculating mice with GL261 cells in the left hemisphere.  
2.3.8. Tumor microenvironment analysis of GL261 tumors in orthotopic GBM 
model 
To assess the immune cell population within the GL261 tumor microenvironment 
in the brain, mice were euthanized two days after the third vaccination, and brains were 
extracted. Tumor mass was dissected and homogenized using Tenbroeck (Corning) 
homogenizer in DMEM media containing 10% FBS. Immune cell populations in the 
tumor microenvironment were enriched with 30%-70% Percoll (GE Lifesciences) density 
gradient. Live/dead staining was carried out using fixable viability dye (eBioscience). 
Non-specific antibody binding was blocked with CD16/CD32. Dendritic cells were 
labeled with CD45, CD11c, and B220 antibodies. Plasmacytoid dendritic cells (pDCs) 
were identified as CD45+/CD11c+/B220+ and conventional dendritic (cDCs) cells were 
identified as CD45+/CD11c+/B220-.  Macrophages were labeled with CD45, F4/80, and 
CD206 antibodies. T cells were labeled with CD45, CD3, CD8 and CD4 antibodies. All 
antibodies were purchased from BioLegend. M1 macrophages were identified as 
CD45+/ F4/80+/ CD206low and M2 macrophages were identified as CD45+/ F4/80+/ 
CD206high. Effector T cells were identified as CD45+/ CD3+/ CD8+ and helper T cells 
were identified as CD45+/ CD3+/ CD4+. T cell exhaustion was assessed by staining for 
anti-PD1.  Regulatory T cells (Tregs) were identified as CD45+/ CD3+/ CD4+/CD25+. All 
stains were carried out for 30min at 4°C with 3X flow buffer washes between live/dead 
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staining, blocking, surface staining, cell fixation, intracellular staining and data 
measurement. All flow measurements have been made utilizing with FACSAria flow 
cytometer (BD Biosciences) and analyzed using Flow Jo version 10 (Treestar).   
2.3.9. Statistical analysis 
Analyses of ELISPOT, FACS, and tumor growth were executed using one-way 
ANOVA tests with Tukey’s post-hoc analyses for multiple comparisons and two-tailed t-
tests for individual group comparisons, all at an alpha level of 0.05. Analyses of survival 
differences were executed using Kaplan-Meier survival analyses with Log-rank Mantel-
Cox tests at an alpha level of 0.05.  
2.4. Results & Discussion 
2.4.1. Three neoantigens were identified as highly immunogenic through in vivo 
screening. 
Three out of six peptides, including the peptide in the sHDL formulation, elicited 
very strong CD8+ T cell responses as evidenced by high IFN-g spot counts (Error! 
Reference source not found.). Two H2-Db-restricted neoantigens, GAIFNGFTL and 
AALLNKYLA, and one H2-Kb-restricted neoantigen, MSLQFMTL, were so immunogenic 
that, when incubated with splenocytes, produced enough IFN-g to reach the maximum 
readable spots per well (3000). Compared to the remaining three peptides, 
GAIFNGFTL, AALLNKYLA, and MSLQFMTL were significantly more immunogenic 








Table 2-1. GL261 neoantigens identified by Johanns et al.117 that were screened by us in vivo to evaluate the 
immunogenicity of each neoantigen by ELISPOT. 
 
2.4.2. Three neoantigens were successfully incorporated into sHDL nanodiscs 
with optimal size for lymphatic delivery.  
Following incorporation of neoantigens AALLNKYLA (GBM1, NeoAg-1), 
MSLQFMTL (GBM2, NeoAg-2), and GAIFNGFTL (GBM3, NeoAg-3) into sHDL 
nanodiscs, each formulation was analyzed by DLS to confirm particle size. Indeed, all 
three neoantigen-loaded sHDL nanodiscs had particle sizes between 9 and 13 nm 
(Figure 2-2), ideal for lymphatic trafficking following administration. GBM1-sHDL had an 
overall positive charge of 3.1 mV while GBM2-sHDL and GBM3-sHDL had overall 
negative charges of -1.81 mV and -3.43 mV, respectively. These zeta potentials reflect 






Epitope restriction Predicted MHC 
affinity 6 
#IFN-g spots/0.5 x 
106 splenocytes 
mTmem2 K1042N VMLENGYTI H-2Db 4.71 42.875 
 
mRtn2 L405F GAIFNGFTL H-2Db 7.76 3000 
 
mImp3 D81N AALLNKLYA H-2Db 42.8 3000 
mNtrk1 H470Q MSLQFMTL H-2Kb 4.69 2266.5 
 
mPcdh18 Q1012R MSSVFRRL H-2Kb 15.22 36.625 
 




predicted by Innovagen’s peptide property calculator118. We also analyzed a mixture, or 
cocktail, of all three neoantigen-loaded sHDL formulations to determine whether the 
formulations would aggregate—they did not. All three formulations mixed well together 
with an average particle size of 12.2 nm and zeta potential of -2.33 mV. This simple test 
allowed us to test the anti-tumor potential of all three neoantigens in one vaccine rather 
than multiple separate vaccines.  
Next, we analyzed each of the three formulations by UPLC/MS and HPLC for 
conjugation efficiency of peptide to lipid and incorporation of peptide-lipid conjugate into 
sHDLs. We found that NeoAg-1, NeoAg-2, and NeoAg-3 were all successfully 
conjugated to DOPE lipid with >99% efficiency as determined by detection of remaining 
DOPE-PDP and its correlation with a standard curve of DOPE-PDP. For incorporation 
of the neoantigens, we found that all three peptide-lipid conjugates were successfully 
inserted into sHDL nanodiscs with >90% incorporation efficiency as determined by 
remaining conjugate in the formulation after purification and removal of free peptide 
(Figure 2-3). Finally, we used GPC to assess the incorporation efficiency of cho-CpG 
into the neoantigen-loaded nanodiscs (NeoAg-Nanodisc) and found >99% incorporation 
as determined by the absence of free cho-CpG peaks and a leftward shift in retention 
time in the NeoAg-Nanodisc peaks, indicating an increase in molecular weight to form 





Figure 2-1. Schematic of the formulation process for NeoAg-loaded sHDL nanoparticles. 
 
 
Figure 2-2. Representative DLS readings for size of each GBM NeoAg-sHDL formulation and table displaying exact 



































Size Distribution by Volume
Record 213: blank HDL 062718 3 Record 284: GBM1HDL May 19 3

















Disposable micro cuvette (40µl)
10 mM Phosphate Buffer

















Measurement Date and Time: 
Record Number: 
















Size Distribution Report by Volume
v2.2




Serial Number : MAL1077751
Zetasizer Ver. 7.11
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Record Number: 213
File name: Example Results
Size (nm) Zeta Potential (mV)
Blank Nanodisc 8.9 ± 2.9 -4.8 ± 1.8
NeoAg1-Nanodisc 9.8 ± 1.6 3.1 ± 2.3
NeoAg2-Nanodisc 13.0 ± 4.0 -1.8 ± 3.1
NeoAg3-Nanodisc 13.1 ± 4.1 -3.4 ± 4.2









Figure 2-3. Representative HPLC chromatogram set for one GBM NeoAg-sHDL formulation. DOPE-NeoAg lipid-
peptide conjugate is shown in red, the pre-purified formulation is shown in blue, the purified formulation is shown in 
green, and blank sHDL is shown in black. 
 
Figure 2-4. GPC chromatogram set for all GBM NeoAg-sHDL formulations after loading adjuvant, cholesterol-
modified CpG. 
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2.4.3. Vaccination with a cocktail of GBM1, GBM2, and GBM3 NeoAgs-CpG-
Nanodisc elicits strong anti-tumor effects in s.c. GL261 tumor-bearing mice  
2.4.3.1. NeoAg-specific CD8+ T cell frequencies are high in mice 
vaccinated with NeoAgs-CpG-Nanodiscs 
ELISPOT analysis of the peripheral blood showed us that a boost vaccination 
increased neoantigen-specific CD8+ T cell expansion 2-to-10-fold compared to prime 
vaccination results in all treatment groups except PBS control, supporting our rationale 
for using the prime-boost treatment regimen in our initial therapeutic studies (Figure 
2-6). Additionally, mice treated with the nanovaccine + anti-PD-L1 exhibited significantly 
greater frequencies of NeoAg-1- and Neo-Ag-2-specific CD8+ T cells after prime and 
boost vaccination compared to mice treated with soluble NeoAgs + anti-PD-L1, 
substantiating the efficacy of sHDL as a nanocarrier for these tumor-specific peptides. 
While NeoAg-3-specific CD8+ T cell frequencies were objectively greater in mice 
treated with nanovaccine +/- anti-PD-L1 compared to mice treated with soluble NeoAgs 
+/- anti-PD-L1, differences were not statistically significant. We believe these results are 
due to competitive binding to MHC-I between NeoAg-1 and NeoAg-3 because the two 
neoantigens have the same H-2 restriction, H-2Db, with NeoAg-1 having a higher 
binding affinity, while NeoAg-2 is H-2Kb restricted. H-2, or histocompatibility 2 molecule, 
is a class I MHC molecule that can be encoded by a variety of genes, including D and 
K, which have different haplotypes, including haplotype b119. This allows for a number of 
different antigens to be presented on MHC-I molecules, but antigens with the same 




Looking again at the ELISPOT results, we expected the lack of statistically 
significant differences in neoantigen-specific CD8+ T cell frequencies between mice 
treated with the nanovaccine + anti-PD-L1 and the nanovaccine alone because anti-PD-
L1 only prevents T cell death and does not induce antigen-specific T cells directly. 
ELISPOT analysis of splenocytes resulted in even more pronounced differences 
between treatment groups compared to the blood, showing significantly greater 
frequencies of NeoAg-1-, Neo-Ag-2-, and NeoAg-3-specific CD8+ T cells after just one 
vaccination in mice treated with the nanovaccine + anti-PD-L1 compared to all other 
treatment groups except for nanovaccine alone (Figure 2-7). These results indicate that 
our nanovaccine induces strong systemic anti-tumor immunity, potentiating production 
of memory T cells and further expansion of neoantigen-specific T cells. Further studies 
must be done to identify frequencies of memory T cells in mice following treatment with 
the nanovaccine, but the strong induction of systemic immunity and the resistance of 




Figure 2-5. Treatment regimen and study timeline for therapeutic vaccination in GL261 s.c. tumor-bearing mice for 
analysis of vaccine immunogenicity.  
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Figure 2-6. IFN-𝛾 ELISPOT of cells in the blood of mice 7 days after prime (left) and boost (right) vaccinations. 
 
Figure 2-7. IFN-𝛾 ELISPOT of cells in the spleen of mice 6 days after prime vaccinations. 
2.4.3.2. NeoAgs-CpG-Nanodiscs + anti-PD-L1 exhibit synergistic tumor 
growth retardation and survival prolongation 
Looking at the effect of each treatment on tumor growth and overall survival, we 
observed that the nanovaccine in combination with anti-PD-L1 immune checkpoint 
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prolonging overall survival (Figure 2-9, Figure 2-10, Figure 2-11). At day 18, the day 
before mice in the PBS control group began reaching the tumor size endpoint, we saw 
complete tumor regression in all mice treated with the nanovaccine + anti-PD-L1, tumor 
growth arrest in mice treated with the nanovaccine and soluble neoantigens + anti-PD-
L1, and slowed tumor growth in mice treated with soluble neoantigens and anti-PD-L1 
alone. As time progressed, one mouse in the nanovaccine + anti-PD-L1 group began 
regrowing a tumor and eventually reached the tumor size endpoint at day 44 to give the 
group a complete response rate of 13/14 (Figure 2-10). Mice treated with either 
nanovaccine alone or anti-PD-L1 alone also experienced impressive tumor regression 
with 50% complete response rates (7/14), supporting the synergistic anti-tumor potential 
of combining neoantigen-loaded sHDL with immune checkpoint blockade. Complete 
response rates for mice treated with the nanovaccine alone (7/14), anti-PD-L1 alone 
(7/14), soluble neoantigens + anti-PD-L1 (5/14), and soluble neoantigens alone (5/14) 
were all similar and not significantly different from each other. The Kaplan-Meier 
analysis of overall survival matches these tumor growth trends, showcasing the synergy 
between treatment with the nanovaccine and anti-PD-L1 (Figure 2-11). 
We observed that combining soluble neoantigen vaccination with immune 
checkpoint blockade offered no therapeutic advantage over soluble neoantigen 
vaccination alone. This observation could possibly be explained by antigen-induced 
tolerance due to substantial antigen deposition at the injection site coupled with poor 
clearance and prolonged T cell exposure to antigen in the absence of co-stimulation. 
This may occur because, in the NeoAgs + CpG + anti-PD-L1 treatment group, 
neoantigens and TLR9 agonist CpG were delivered separately without co-loading on 
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sHDL. In this setting, CpG could be inefficiently delivered to DCs, resulting in less DC 
maturation and subsequent stimulation of T cells 16,120-122. Without DC stimulation via B7 
molecular interactions with CD28 in the presence of neoantigen, T cells could become 
tolerant, downregulating their CD8 expression and converting to an anergic population 
or undergoing clonal deletion122. Treatment with anti-PD-L1 would then be irrelevant 
without active neoantigen-specific T cell populations to protect from tumor cell-mediated 
death. Fortunately, co-delivery of neoantigens and CpG adjuvant via sHDL seemed to 
overcome these potential mechanisms of tolerance as its combination with anti-PD-L1 
showed synergistic anti-tumor efficacy.  
Of the mice treated with nanovaccine + anti-PD-L1, complete responders were 
rechallenged with the original dose of tumor cells in the contralateral flank and exhibited 
no tumor recurrence, suggesting generation of immune memory (Figure 2-12). 
Researchers have shown that, in mice, memory T cells can be generated as soon as 3 
days after initial vaccination and expand dramatically as soon as 1 week after boost 
vaccination123,124. In fact, effector memory T cells, the cells residing in non-lymphoid 
tissues, are more likely to develop after T cells’ second exposure to antigen while 
central memory T cells residing in lymphoid tissues are more likely develop after T cells’ 
first antigen exposure. Long-term survival of memory T cells, however, is not well 
understood. Yet, it is clear in our studies that memory cell populations remained active 
for several weeks after the last vaccination.  Additional studies must be done to identify 
frequencies of memory T cells in mice following treatment with our nanovaccine, but the 
strong induction of systemic immunity as shown in ELISPOT analyses and the 
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resistance of long-term survivors to tumor rechallenge suggest that these memory cells 
do, in fact, exist.  
 
 
Figure 2-8. Treatment regimen and study timeline for therapeutic vaccination in GL261 s.c. tumor-bearing mice for 
evaluation of tumor growth and survival.  
 
 
Figure 2-9. Tumor growth summary for all treatment groups up to day 18. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001. 
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Figure 2-10. Individual tumor growth curves for all animals in the study through the duration of the study. 
 
Figure 2-11. Kaplan-Meier overall survival curve for all treatment groups. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001. MS = median survival.  
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Figure 2-12. Kaplan-Meier survival curve of rechallenged mice in the NeoAgs-CpG-Nanodisc + anti-PD-L1 treatment 
group compared to naïve mice inoculated with tumors for the first time. ****P<0.0001. MS = median survival. 
2.4.4. Vaccination with a cocktail of GBM1, GBM2, and GBM3 NeoAgs-CpG-
Nanodisc reverses the immunosuppressive tumor microenvironment 
We found that the mice treated with neoantigen peptide-loaded nanodiscs 
recruited significantly more CD8+ T cells (p < 0.0001), activated CD107a+ CD8+ T cells 
(p < 0.001), and activated CD86+ dendritic cells (p < 0.001) to the tumor site as 
compared to untreated controls. These mice also exhibited significantly greater 
intratumoral ratios of CD8+ T cells to FoxP3+ CD4+ Tregs compared to mice vaccinated 
with soluble neoantigen peptides (p < 0.05) and untreated controls (p < 0.01). No 
significant differences in CD4+ T cell or Treg frequencies were observed between 
groups. PD-1 expression by CD8+ T cells in nanodisc-treated was significantly reduced 
(p < 0.01) compared to untreated control. Though statistically insignificant, soluble 




















NeoAgs + CpG + anti-PD-L1 vaccination also decreased PD-1 expression by CD8+ T 
cells compared to untreated control, the difference being about 1.2-fold lower for soluble 
vaccination versus 1.4-fold lower for nanodisc vaccination. This trend in PD-1 
expression could, in part, explain how our nanovaccine in combination with immune 
checkpoint blockade is so effective. It would also be interesting to evaluate whether 
CTLA-4 expression by CD8+ T cells, another marker of T cell exhaustion, is also 
significantly decreased in mice treated with our nanovaccine or whether anti-CTLA-4 
vaccination would be needed for such a result1.  
Taken together, these results tell us that treating mice with neoantigen peptide-
loaded nanodiscs in combination with anti-PD-L1 significantly shifts the balance 
between pro-tumor and anti-tumor immunity within the tumor microenvironment away 
from immunosuppression towards an immunostimulatory environment when compared 
to treatment with soluble neoantigen peptides in combination with anti-PD-L1. 
Moreover, the decreased PD-1 expression by CD8+ T cells reduces the probability of 
tumor-induced T cell death through ligation with PD-L1 on tumor cells, which in turn 
increases the probability of CD8+ T cell activation and neoantigen-specific tumor cell 
killing. With one of the cruxes of tumor progression and recurrence being the unchecked 
immunosuppressive tumor microenvironment, the shift we observed gives our 
nanovaccine promise for succeeding as a novel, effective treatment that ensures 
increased tumor-specific CD8+ T cell and activated dendritic cell infiltration and 
decreased proportions of regulatory T cells. Despite the exciting in vivo results we 
observed in s.c. GL261 tumor models, we know that the model does not serve justice to 
the complexity of true glioblastomas in the brain. Thus, we proceeded to test our 
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nanovaccine’s efficacy in an orthotopic GBM mouse model to represent a more 
accurate therapeutic setting.  
 
 
Figure 2-13. Treatment regimen and study timeline for tumor microenvironment analysis of GL261 s.c. tumors.  
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Figure 2-14. Immune activation within the tumor microenvironment after NeoAgs-CpG-Nanodisc plus anti-PD-L1 
therapy. A-E) C57BL/6 mice inoculated s.c. with 1.2 X 106 GL261 tumor cells were vaccinated on day 20 and 
administered with anti-PD-L1 on days 21 and 24. Tumor tissues were stained with antibodies and analyzed by flow 
cytometry for CD8a+ T-cells, Tregs, and DCs.. *P<0.05, **P<0.01, *** P < 0.001, ****P<0.0001. 
 
2.4.5. Vaccination with a cocktail of GBM1, GBM2, and GBM3 NeoAgs-CpG-
Nanodisc prolongs survival in a GL261 orthotopic model 
In our pilot study, we observed a significant increase in overall survival in mice 
treated with our nanovaccine in combination with anti-PD-L1 compared to mice treated 
with soluble neoantigen peptides in combination with anti-PD-L1 (Figure 2-16) with a 
~1.4-fold increase in median survival. We also rechallenged the long-term survivor in 
the nanovaccine treatment group. After 30 days of observation, the rechallenged mouse 
did not exhibit any signs of morbidity, suggesting the nanovaccine’s elicitation of anti-
tumor immune memory. More studies must be done to validate this hypothesis, but we 
first proceeded to improve overall survival further by adjusting the treatment regimen.  
 In our second therapeutic study, we observed the same overall survival trends as 
seen in the pilot study, once again increasing median survival ~1.4-fold when comparing 
nanovaccine-treated mice to soluble neoantigen-treated mice (Figure 2-18). Also, the 
long-term survivor was rechallenged as done in the pilot study and again showed no 
signs of morbidity, suggesting anti-tumor immune memory was induced by our 
nanovaccine. To investigate the immunogenicity of our nanovaccine in GL261 brain 
tumor-bearing mice, we also took blood samples from the mice in the survival study to 
run IFN-𝜸 ELISPOT and determine the frequencies of neoantigen-specific CD8+ T cells. 
We observed 4-to-10-fold higher frequencies of neoantigen-specific CD8+ T cells 
across all three neoantigens in mice treated with our nanovaccine compared to soluble 
neoantigen peptides (Figure 2-19), which followed the trends observed in our 
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subcutaneous GBM mouse model. Significant increases in neoantigen-specific CD8+ T 
cell frequencies were observed in mice treated with nanodiscs compared to soluble 
peptides or PBS after the second and third vaccinations (Figure 2-19). Larger 
differences between groups may be seen if the sample size is increased as the 
ELISPOT assays included only 4-5 samples per group. Nonetheless, these results 
mean that our nanovaccine is indeed more effective than soluble neoantigens in the 
induction of neoantigen-specific CD8+ T cells.  
 
 
Figure 2-15. Pilot study treatment regimen and study timeline for evaluation of anti-tumor efficacy of GBM NeoAg 
vaccination on orthotopic GL261 tumor-bearing mice.  
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Figure 2-17. Second therapeutic study treatment regimen and study timeline for evaluation of anti-tumor efficacy of 
GBM NeoAg vaccination on orthotopic GL261 tumor-bearing mice.  
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Figure 2-18. Kaplan-Meier overall survival curve for all treatment groups in second therapeutic study. ****P<0.0001.  
 
 
Figure 2-19. IFN-𝛾 ELISPOT of cells in the blood of GL261 brain tumor-bearing mice 6 days after the second and 
third vaccinations. *P<0.05, **P<0.01. 
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2.4.6. Vaccination with a cocktail of GBM1, GBM2, and GBM3 NeoAgs-CpG-
Nanodisc reverses immunosuppression in a GL261 orthotopic model 
Analysis of the brain tumor microenvironments of mice vaccinated with NeoAgs-
CpG-Nanodisc + anti-PD-L1 revealed significant increases in frequencies of CD8+ T 
cells (p<0.0001) and significant decreases in frequencies of Tregs (p<0.001), M1 
(p<0.001) and M2 (p<0.01) macrophages, and PD1+ CD8+ T cells (p<0.0001) when 
compared to untreated controls (Figure 2-20). No differences in CD4+ T cell or activated 
DC frequencies were observed. Overall, these results were consistent with our tumor 
microenvironment analysis of subcutaneous flank tumors. The increase in CD8+ T cells 
and decreases in PD1+ CD8+ T cells and Tregs together indicated a reversal of 
immunosuppression within the brain tumors of mice treated with our nanovaccine + anti-
PD-L1. Additionally, the decreased frequencies of macrophages within the tumors, also 
known as tumor-associated macrophages (TAMs), of the mice treated with our 
nanovaccine + anti-PD-L1 could also contribute to the reversal of immunosuppression 
that is typically induced by TAMs. In the future, more in-depth cytokine analysis of tumor 
tissue could be conducted to understand fully the mechanisms by which 
immunosuppression was reversed to improve overall survival of the mice treated with 





Figure 2-20. Tumor microenvironment analysis of GBM tumors in CNS. A-E) C57BL/6 mice were inoculated with 
GL261 cells and treated, and GBM tumors were isolated and analyzed by flow cytometry. Shown are A) CD8a T cells 
among all T cells, B) PD-1 receptor expression on CD8a+ T cells, C) CD25+CD4+ regulatory T cells, D) ratio of 
CD8a+ T cells to regulatory T cells, and E) the ratio of M1 (CD206- F4/80+) to M2 (CD206+ F4/80+) macrophages. 
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Chapter 3. Optimization of the formulation process for 
neoantigen-loaded sHDL nanodiscs through alteration of 
peptide physicochemical properties 
3.1. Abstract 
The current formulation process for neoantigen-loaded sHDL nanodiscs is complex, 
involving multiple lyophilization and pH adjustment steps that could result in material 
loss upon product transfer between vials and excessive titration time, respectively. A 
simpler formulation process is desirable for clinical translation of this neoantigen 
delivery platform (Figure 3-1). Methods that can be employed for such formulation 
simplification include directly conjugating lipid to neoantigen peptide in rehydration 
solvent to eliminate lyophilization, increasing neoantigen water solubility to reduce the 
use of organic solvents altogether, and exploiting electrostatic interactions between 
neoantigen peptides and adjuvant to eliminate the use of lipid anchor altogether.  
In this chapter, we employed all of these methods separately to determine whether 
(1) formulation simplification is feasible and (2) immunogenicity of neoantigen loaded is 
retained for each method using model MC38 colon adenocarcinoma neoantigen Adpgk. 
 
We found that two methods, directly conjugating lipid to neoantigen peptide in 
DMSO and increasing neoantigen solubility through PEGylation, worked well to reduce 
formulation process complexity and completion time while also retaining neoantigen 
immunogenicity as compared to the traditional formulation method. Proceeding with the 
PEGylation method, we compared the immunogenicity of second MC38 neoantigen 
Reps1 along with Adpgk between traditional and PEGylated formulation methods. 
Again, we found that PEGylated formulations were comparable to traditional 
formulations for both neoantigens with respect to the generation of neoantigen-specific 
CD8+ T cells. Taking formulation comparison a step further, we challenged all mice that 
had been prophylactically vaccinated with each of the formulations with MC38 tumor 
cells. Between traditional and PEGylated formulations, no significant differences in 
median survival were observed for either neoantigen, indicating similar anti-tumor 
protection between traditional and PEGylated formulations.  
In full, these studies have revealed that the currently complex neoantigen-loaded 
sHDL formulation can be simplified by adding a small PEG chain to the end of the 
neoantigen peptide sequence and that such a modification has no effect on the 
immunogenicity of the neoantigen itself. The protective anti-tumor immunities of the 
PEGylated and traditional formulations were comparable for both neoantigens, 
supporting our hypothesis that simplifying the formulation could make the sHDL platform 





Figure 3-1. Comparative flow charts explaining the current and desired formulation processes for neoantigen-loaded 
sHDL nanodiscs.  
3.2. Introduction 
One of the major obstacles of delivering neoantigen peptides is the peptides’ 
solubility, which directly affects the peptides’ trafficking and lymphatic delivery. Water-
soluble peptides, which have greater proportions of charged residues, are quite easy to 
deliver because they can be injected with just about any buffering solution that is 
currently used in clinical settings. Water-insoluble peptides, however, are more common 
and much more difficult to deliver due to their hydrophobicity and their potential to form 
micelles, a structure that cannot be incorporated into nanoparticle platforms such as our 
synthetic HDL nanovaccine platform, or aggregates. 
This results in only a minor fraction of the peptide dose reaching the target lymphoid 
tissues, limiting overall vaccine efficacy. Knowing this, we have modified our process for 
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neoantigen peptide loading onto synthetic HDL nanoparticles to include lipid conjugation 
in organic solvents and pH adjustment of the particle solution prior to peptide addition to 
increase peptide solubility. The full neoantigen peptide-loaded synthetic HDL 
formulations can usually be worked back to a neutral pH following purification for safe 
administration of the nanovaccines, but some peptides are more stubborn and require 
maintenance in strongly acidic or basic conditions. Unfortunately, acidic conditions 
cause precipitation of our CpG oligonucleotide adjuvants, and basic conditions cause 
inflammation and abscess formation at the injection site. Moreover, removal of organic 
solvent from reaction mixtures and rehydration of reaction products combined with 
product transfer between vials results in some product loss. Taken together, we have 
learned that we cannot, at this time, classify peptides into categories of one formulation 
method versus another and need to find a simpler way to streamline the production of 
neoantigen peptide-loaded synthetic HDLs.  
Fortunately, poly(ethylene glycol) has been demonstrated in many drug delivery 
applications, especially in cancer, to be a solubilizing polymer for hydrophobic drug 
molecules125,126-129, likely due to PEG’s rearrangement of water molecules through 
hydrogen bonding. Thus, we hypothesized that 1) functionalizing hydrophobic peptides 
would increase these peptides’ hydrophilicity, enabling simpler loading onto our 
synthetic HDL nanoparticles in aqueous solutions for more efficient synthesis and 
reduced material loss. We also hypothesized that 2) the PEGylated peptides would 
have comparable, if not better, immunogenicity to the original peptide in vivo. 
Table 3-1. CSS-modified Adpgk (ASMTNMELM) and Reps1 (AQLANDVVL) neoantigen peptide properties predicted 
by pepcalc.com.  
 
Sequence total # residues #charged residues #ionizable residues # hydrophobic residues % hydrophobic MW pI (estimated)
CSSASMTNMELM 12 1 2 5 41.67% 1304.54 1
CSSAQLANDVVL 12 1 2 6 50.00% 1219.4 0.69
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3.3. Materials & Methods 
3.3.1. Materials 
HS-(PEG)8-KSSASMTNMELM (PEG8-Adpgk), HS-(PEG)8-KSSAQLANDVVL 
(PEG8-Reps1), HS-(PEG)4-KSSASMTNMELM (PEG4-Adpgk), and HS-(PEG)4-
KSSAQLANDVVL (PEG4-Reps1) were synthesized by and purchased from Genemed 
Synthesis, Inc. CSSASMTNMELM (Adpgk) and CSSAQLANDVVL (Reps1) ) were 
synthesized by and purchased from RS Synthesis. RRRRRRRRR-CSS-ASMTNMELM 
(R9-Adpgk) and CSS-ASMTNMELM-RRRRRRRRR (Adpgk-R9) were synthesized by 
and purchased from RS Synthesis. Apolipoprotein A1 mimetic peptide 22A was 
synthesized by GenScript. 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) was 
purchased from NOF America. 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[3-(2-
pyridyldithio)propionate] (DOPE-PDP) was purchased from Avanti Polar Lipids. 
Cholesterol-modified CpG1826 was synthesized by Integrated DNA Technologies.  
C57BL/6 female mice, aged 5-6 weeks, were purchased from Jackson 
Laboratories. MC38 cells were purchased from Kerafast. HPLC was performed using a 
Thermo Scientific™ BioBasic™ Phenyl HPLC Column. UPLC/MS was performed using 
either an Acquity UPLC® BEH HILIC 1.7 µm 2.1 x 50 mm column or an Acquity UPLC® 
BEH300 C4 1.7 µm 2.1 x 150 mm column. GPC was performed using a TSKgel 
G3000SWxl column from Tosoh Bioscience. Adpgk tetramer was generously provided 
by NIH.  
3.3.2. Formulation of Adpgk-sHDL using different simplification methods 
In the traditional formulation, the lipid-peptide conjugate and sHDL were 
synthesized in parallel processes. DOPE-PDP lipid was reconstituted in DMF, added 
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directly to Adpgk peptide powder, and reacted for 3 hours at room temperature on an 
orbital shaker. The reaction mixture was then diluted with ultrapure water, flash frozen, 
and lyophilized overnight. While sHDL was reconstituted in 10 mM sodium phosphate 
buffer and thermocycled to form nanodiscs, the dried lipid-peptide conjugate was 
reconstituted in DMSO at a concentration equivalent to 2 mg/mL DOPE-PDP. Finally, 
the sHDL solution’s pH was adjusted with ammonium hydroxide to a final concentration 
of 0.075 M ammonium hydroxide to facilitate peptide solubility, and the lipid-peptide 
DMSO solution was then added to the sHDL solution and allowed to incubate for at 
least 1 hour at room temperature on an orbital shaker. The final formulation was purified 
using 10 kDa MWCO centrifugal filters.  
In the DMSO formulation, DMF was simply replaced with DMSO, the solvent 
used to reconstitute the lyophilized lipid-peptide conjugate, to allow for direct 
conjugation of lipid to peptide in DMSO followed by direct addition of the lipid-peptide 
solution to sHDL. The purification process remained the same for the DMSO formulation 
as for the traditional formulation.  
In the PEGylated formulation, no organic solvents were used at all. This method 
could potentially go without purification if the lipid-peptide conjugation was efficient 
enough at lower peptide-to-lipid molar ratios. Nonetheless, we tested three different 
lipid-to-peptide molar ratios in the PEGylated formulation process to determine the 
optimal ratio (Figure 3-4, Figure 3-5, Figure 3-6). For this formulation, DMPC and 
DOPE-PDP were dissolved in chloroform and combined with 22A dissolved in 
methanol. The organic solvents in the mixture were evaporated under nitrogen gas, and 
the dried film was reconstituted in 5 mM sodium phosphate buffer to form sHDL-PDP. 
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Simultaneously, PEGylated Adpgk was reconstituted in ultrapure water at 2 mg/mL, 
subsequently added directly to sHDL-PDP, and left to incubate on an orbital shaker for 
2 hours at room temperature. The purification process remained the same for the 
PEGylated formulation as for the traditional formulation. 
In the Adpgk-R9 and R9-Adpgk formulations, blank sHDL was made in 10 mM 
sodium phosphate buffer, and cholesterol-modified CpG1826 (cho-CpG) was inserted 
into sHDL by simple mixing (CpG-sHDL). Either Adpgk-R9 and R9-Adpgk were then 
reconstituted in water and mixed with CpG-sHDL at 150 µg/mL peptide and 300 µg/mL 
cho-CpG, a mass ratio determined to be optimal based on DLS size analysis of particles 
formed (~10 nm being ideal) using several different mass ratios of peptide to cho-CpG 
(Figure 3-8, Table 3-2). The formulations were not purified.  
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3.3.3. Chromatographic analysis of different sHDL formulations 
Three different chromatographic analyses were used: HPLC, UPLC/MS, and 
GPC. For HPLC analysis, samples were diluted in 50/50 methanol/acetonitrile + 0.1% 
trifluoroacetic acid (TFA) and filtered through PTFE syringe filters. Samples were run in 
40 µL volumes on a reverse-phase BioBasic™ phenyl column for 100 minutes at 0.4 
mL/min. Peak areas were analyzed at 220 nm. To determine neoantigen peptide-lipid 
conjugation efficiency, peak areas corresponding to DOPE-PDP (~83 min) were 
compared between DOPE-PDP alone or sHDL-PDP samples and neoantigen-DOPE or 
PEGylated neoantigen-sHDL samples. To determine neoantigen loading efficiency, 
peak areas corresponding to neoantigen-DOPE (various elution times ~78-81 min) were 
compared between pre-purified and purified samples.  
For UPLC/MS analysis, conjugation efficiency was determined using a HILIC 
column. Samples were run in 5 µL volumes for 5 minutes, and peak areas at 941.81 Da 
corresponding to DOPE-PDP (MW DOPE-PDP – MW sodium ion + 1) were compared 
between DOPE-PDP alone and neoantigen-DOPE samples. Incorporation efficiency 
was determined using a C4 column on which samples were run in 5 µL volumes for 14 
minutes. Peak areas corresponding to neoantigen-DOPE conjugates were compared 
between pre-purified and purified samples. Mass channels for conjugate detection were 
determined by different fractions of MW neoantigen + MW DOPE lipid + 1 (Error! 
Reference source not found.).  
For GPC analysis, incorporation efficiency of cho-CpG or complexation of 
arginine-tagged neoantigen peptide with CpG was determined by running samples in 30 
µL volumes for 20 minutes and comparing the peak areas of either neoantigen-loaded 
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sHDL samples before and after cho-CpG addition or sHDL/CpG samples before and 
after arginine-tagged neoantigen peptide. A leftward shift in retention time was also 
indicative of successful incorporation or complexation due to increased molecular 
weight. 
3.3.4. Justification of model for testing PEGylated-NeoAg-sHDL 
To test our hypotheses on PEGylating neoantigen peptides for the simplification of 
sHDL formulations, we thought it best to choose a well-established neoantigen model--
MC38 colon adenocarcinoma. In 2014, Yadav et al. published their impressive findings 
on neoantigen identification in MC38 and TRAMP-C1 mouse tumors using next 
generation exome sequencing. MC38 tumors exhibited much greater mutational 
frequencies than did TRAMP-C1 tumors, and just seven neoepitopes in MC38 tumors 
were found to bind MHC-I while no TRAMP-C1 neoepitopes were found to do so. 
Therefore, the study proceeded with closer examination of the MC38 neoepitopes. Out 
of the seven MHC-I neoepitopes identified, five were predicted to have high MHC-I 
binding affinities, and two of these five--Adpgk and Reps1--possessed mutated residues 
between the 3rd and 7th amino acid in their peptide sequences, a location known to be of 
primary recognition by TCRs38,130. Since this publication, myriad research groups have 
been using Adpgk and Reps1 neoantigens to study and develop precision cancer 
immunotherapy methods and applications131. Moreover, our lab has published several 
works on cancer immunotherapy using the Adpgk neoantigen16,90,132. 
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3.3.5. Prophylactic treatment regimen for comparison of immunogenicity 
between formulations 
Female C57BL/6 mice were vaccinated with each of the formulations (n = 5) 
subcutaneously at the tail base on a biweekly basis with 15 𝜇g peptide and 15 𝜇g CpG 
per vaccination (Figure 3-11). Nanodisc formulations were diluted to 0.15 mg/mL 
NeoAg, including the volume of CpG added, for 100 𝜇𝐿 s.c. injections. NeoAg peptides 
were dissolved in 10 mM sodium phosphate buffer and diluted to 0.15 mg/mL NeoAg, 
including the volume of CpG added, for 100 𝜇𝐿 s.c. injections. Mice were challenged 
with 1.5 x 106 MC38 cells in the right flank 18 days after the last prophylactic 
vaccination to test the anti-tumor immunity established by prophylactic vaccination.  
3.3.6. Statistical analysis 
Analyses of ELISPOT, FACS, and tumor growth were executed using one-way 
ANOVA tests with Tukey’s post-hoc analyses for multiple comparisons and two-tailed t-
tests for individual group comparisons, all at an alpha level of 0.05. Analyses of survival 
differences were executed using Kaplan-Meier survival analyses with Log-rank Mantel-
Cox tests at an alpha level of 0.05.  
 
3.4. Results & Discussion 
3.4.1. Analysis of formulations using multiple methods of simplification with 
Adpgk neoantigen 
We used HPLC to analyze the traditional, DMSO, and PEGylated formulations 
for conjugation of peptide to lipid and incorporation of the peptide into sHDL (Figure 3-2, 
Figure 3-3, Figure 3-7). In the HPLC chromatograms, 22A is visible at 68 minutes, 
 
 76 
DMPC at 76 minutes, and DOPE-PDP at 83 minutes. We used GPC to analyze the 
Adpgk-R9 and R9-Adpgk formulations for complexation of the peptides with CpG-sHDL 
(Figure 3-9, Figure 3-10). In the GPC chromatograms, CpG-sHDL is visible at 8 
minutes. We achieved overall neoantigen incorporation efficiencies of 97% for the 
traditional formulation, 96% for the DMSO formulation, and 90% for the PEGylated 
formulation. These were calculated by multiplying the lipid-peptide conjugation 
efficiency, determined by the concentration of DOPE-PDP leftover, by the conjugate 
retention percentage after purification. We also achieved some successful complexation 
between Adpgk-R9 or R9-Adpgk and CpG-sHDL as indicated by the leftward shift in 
retention time of the sHDL nanodiscs following incubation with either one of the 
polyarginine-functionalized Adpgk peptides. The GPC charts shown are representative 
of 2 out of the 9 different mass ratios we tested to achieve maximum complexation. The 
final mass ratio chosen for both Adpgk-R9/CpG-sHDL and R9-Adpgk/CpG-sHDL was 
150 µg/mL peptide and 300 µg/mL CpG based on both DLS results showing ~10 nm 
nanodisc formation and on GPC results showing a decrease in peak area for CpG-
sHDL around 8 minutes and an increase in peak area for complexed Adpgk-R9/CpG-




Figure 3-2. HPLC analysis of traditional formulation (l = 220 nm). (A) free Adpgk peptide (B) DOPE-Adpgk conjugate 
(C) Adpgk-sHDL before purification (D) Adpgk-sHDL after purification. 
 
Figure 3-3. HPLC analysis of DMSO formulation (l = 220 nm). (A) DOPE-PDP (B) free Adpgk peptide (C) Adpgk-
sHDL before purification (D) Adpgk-DOPE conjugate. 

































Figure 3-4. HPLC analysis of PEGylated formulation using low molar ratio (1.5:1) of PEG4-Adpgk peptide to DOPE-
PDP lipid (l = 220 nm). (A) sHDL-PDP (B) DOPE-PDP (C) free PEGylated Adpgk peptide (D) PEGylated Adpgk-
sHDL before purification (E) PEGylated Adpgk-sHDL after purification. 
 
Figure 3-5. HPLC analysis of PEGylated formulation using medium molar ratio (2:1) of PEG4-Adpgk peptide to 
DOPE-PDP lipid (l = 220 nm). (A) sHDL-PDP (B) DOPE-PDP (C) free PEGylated Adpgk peptide (D) PEGylated 
Adpgk-sHDL before purification (E) PEGylated Adpgk-sHDL after purification. 





































Figure 3-6. HPLC analysis of PEGylated formulation using high molar ratio (2.5:1) of PEG4-Adpgk peptide to DOPE-
PDP lipid (l = 220 nm). (A) sHDL-PDP (B) DOPE-PDP (C) free PEGylated Adpgk peptide (D) PEGylated Adpgk-
sHDL before purification (E) PEGylated Adpgk-sHDL after purification. 
 
Figure 3-7. HPLC analysis of scaled-up large batch of PEGylated formulation using low molar ratio (1.5:1) of PEG4-
Adpgk peptide to DOPE-PDP lipid (l = 220 nm). (A) free PEGylated Adpgk peptide (B) DOPE-PDP (C) PEGylated 
Adpgk-sHDL before purification (D) PEGylated Adpgk-sHDL after purification. 
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Figure 3-8. DLS size analysis of all attempted formulations using arginine-tagged Adpgk.  
 
Figure 3-9. GPC analysis of Adpgk-R9 formulation (l = 260 nm). (A) CpG-sHDL (B) free Adpgk-R9 peptide (C) 
Adpgk-R9/CpG-sHDL at 150 µg/mL peptide, 150 µg/mL CpG (D) Adpgk-R9/CpG-sHDL at 75 µg/mL peptide, 150 
µg/mL CpG.  
Formulation 13: Adpgk-R9 300 µg/mL + CpG-sHDL 450 µg/mL Formulation 14: R9- Adpgk 300 µg/mL + CpG-sHDL 450 µg/mL
Formulation 15: Adpgk-R9 150 µg/mL + CpG-sHDL 450 µg/mL Formulation 16: R9- Adpgk 150 µg/mL + CpG-sHDL 450 µg/mL
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Figure 3-10. GPC analysis of R9-Adpgk formulation (l = 260 nm). (A) CpG-sHDL (B) free R9-Adpgk peptide (C) R9-
Adpgk/CpG-sHDL at 150 µg/mL peptide, 150 µg/mL CpG (D) R9-Adpgk/CpG-sHDL at 75 µg/mL peptide, 150 µg/mL 
CpG.  
 
3.4.2. DMSO and PEGylated formulations exhibit immunogenicity similar to the 
traditional formulation in a prophylactic setting. 
First, we decided to perform a prophylactic vaccination study to determine the 
immunogenic potential of each formulation relative to the traditional formulation, which 
our lab has previously demonstrated. We did this by comparing the frequency of Adpgk-
positive CD8+ T cells among each group of female C57BL/6 mice vaccinated with each 
of the formulations subcutaneously at the tail base on a biweekly basis (Figure 3-11). 
We found that, after the second and third vaccinations, frequencies of Adpgk-positive 
CD8+ T cells in the peripheral blood of mice treated with either the DMSO or PEGylated 
formulations were comparable to those in the blood of mice treated with the traditional 
formulation. Mice treated with either the Adpgk-R9 or R9-Adpgk formulations, however, 



















did not demonstrate these similarities and instead showed 4-fold and 8-fold lower 
frequencies of Adpgk-positive CD8+ T cells after the second and third vaccinations 
compared to mice treated with the traditional formulation (Figure 3-12). In summary, the 
results indicated that the Adpgk-R9 and R9-Adpgk formulations were not worth pursuing 
as simplified formulation methods due to their diminished immunogenicity while the 
DMSO and PEGylated formulations showed promising immunogenic similarities to the 
traditional formulation. However, the mice treated with the DMSO formulation exhibited 
somewhat lower Adpgk-positive CD8+ T cells than did mice treated with the PEGylated 
formulation, and we also were concerned about oxidation of the Adpgk peptide during 
formulation with DMSO given the three oxidation-prone methionine residues on the 
peptide. Thus, we decided to proceed with the PEGylated formulation as a simplification 
solution. We also selected another MC38 neoantigen to test, Reps1, to validate the 
merit of our simplification solution. All further studies utilize both Adpgk and Reps1 in 
PEGylated and non-PEGylated forms.  
 
 
Figure 3-11. Treatment regimen and study timeline for prophylactic vaccination study using different formulation 









Figure 3-12. FACS analysis of PBMCs showing frequencies of Adpgk-specific CD8+ T cells in systemic circulation 1 
week after each vaccination. *P<0.05.  
3.4.3. Analysis of PEG4-Adpgk and PEG4-Reps1 nanodisc formulations 
Formulations were quantified using HPLC, showing successful conjugation to 
DOPE and retention of the conjugate after purification. We achieved 84% conjugation 
efficiency and 75% conjugate retention after purification for a 63% overall incorporation 
efficiency in the PEG(4)-Reps1-sHDL formulation (Figure 3-13) and 98% conjugation 
efficiency and 84% conjugate retention after purification for an 82% overall incorporation 
efficiency in the PEG(4)-Adpgk-sHDL formulation (Figure 3-14). In the HPLC 
chromatograms, 22A is visible at 68 minutes, DMPC at 76 minutes, and DOPE-PDP at 
83 minutes. Traditional formulations were analyzed by UPLC/MS (Error! Reference 
source not found.). We also used DLS to perform size analysis of our formulations and 
found that, after loading cho-CpG onto PEG(4)-Reps1-sHDL and PEG(4)-Adpgk-sHDL, 
the nanodiscs retained an ideal size of 8-12 nm for effective lymphatic drainage (Table 
3-3).  




























































Figure 3-13. HPLC analysis of PEG4-Reps1 formulation (l = 220 nm). (A) blank sHDL (B) DOPE-PDP (C) PEGylated 
Reps1-sHDL before purification (D) PEGylated Reps1-sHDL after purification. 
 
Figure 3-14. HPLC analysis of PEG4-Adpgk formulation (l = 220 nm). (A) blank sHDL (B) DOPE-PDP (C) PEGylated 
Adpgk-sHDL before purification (D) PEGylated Adpgk-sHDL after purification. 
 








































Figure 3-15. GPC analysis of PEG4-Reps1 formulation following cho-CpG loading. Free cho-CpG is shown in red, 
PEG4Reps1-sHDL before cho-CpG loading in shown in blue, PEG4Reps1-sHDL after cho-CpG loading is shown in 
green.  
 
Figure 3-16. GPC analysis of PEG4-Adpgk formulation following cho-CpG loading. Free cho-CpG is shown in red, 











Figure 3-17. GPC analysis of Reps1 formulation following cho-CpG loading. Free cho-CpG is shown in red, Reps1-
sHDL before cho-CpG loading in shown in blue, Reps1-sHDL after cho-CpG loading is shown in green.  
 
Figure 3-18. GPC analysis of Adpgk formulation following cho-CpG loading. Free cho-CpG is shown in red, Adpgk-
sHDL before cho-CpG loading in shown in blue, Adpgk-sHDL after cho-CpG loading is shown in green. 
Table 3-3. Summary of size and zeta potential of PEGylated and traditional Reps1 and Adpgk neoantigen-loaded 








Formulation Size +/- SD (nm) Zeta Potential +/- SD (mV)
PEG(4)Reps1-sHDL/cho-CpG 9.384 +/- 2.349 -9.15 +/- 3.72
Reps1-sHDL/cho-CpG 11.23 +/- 2.527 -8.35 +/- 4.41
PEG(4)Adpgk-sHDL/cho-CpG 9.936 +/- 2.613 -5.87 +/- 6.32
Adpgk-sHDL/cho-CpG 9.831 +/- 2.856 -5.14 +/- 7.69
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3.4.4. PEG4-Adpgk and PEG4-Reps1 are just as immunogenic as Adpgk and 
Reps1 when delivered on sHDL nanodiscs 
We performed a prophylactic vaccination study to determine the immunogenic 
potential of PEGylated neoantigen formulations relative to the traditional formulation 
with free neoantigen peptide as a control. We compared the frequency of Reps1- or 
Adpgk-specific CD8+ T cells among each group using IFN-𝛾 ELISPOT. We found that, 
for both Adpgk and Resp1 neoantigens, mice vaccinated with PEGylated and traditional 
formulations exhibited comparably strong neoantigen-specific CD8+ T cell responses 
after all three vaccinations (p>0.05). Both PEGylated and traditional formulations 
induced significantly greater neoantigen-specific CD8+ T cell responses than did soluble 
neoantigen for Adpgk and Reps1, which is consistent with previous results in this 
chapter and in Chapter 2 (Figure 3-19). Taken together, these results support our 
hypothesis that PEGylated neoantigen-loaded sHDL would maintain vaccine 




Figure 3-19. IFN-𝛾 ELISPOT of PBMCs showing frequencies of neoantigen-specific CD8+ T cells in systemic 
circulation 1 week after each vaccination. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.  
 
3.4.5. PEGylated and traditional formulations exhibited comparable protective 
anti-tumor immunity 
Taking formulation comparison a step further, we challenged all prophylactically 
vaccinated mice with MC38 tumor cells in the flank 11 days after the third vaccination. 
Between traditional and PEGylated formulations, significant differences in tumor growth 
were only observed with Adpgk neoantigen (day 20, p<0.05) (Figure 3-20). At earlier 
time points, prophylactic treatment with PEG4Adpgk-sHDL/CpG slowed tumor growth 
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more effectively than did Adpgk-sHDL/CpG, but this effect did not last past day 20. After 
day 20, mice began reaching tumor end points, rendering further tumor growth 
comparisons inaccurate. Median survival rates for each vaccination group were similar: 
PEG4Reps1-sHDL/CpG, 23 days; Reps1-sHDL/CpG, 22 days; free Reps1 + CpG, 23 
days; PEG4Adpgk-sHDL/CpG, 30 days; Adpgk-sHDL/CpG, 26 days; free Adpgk + CpG, 
31 days. No significant differences in median survival were observed between 
formulations for either neoantigen (Figure 3-21), indicating similar anti-tumor protection 
between traditional and PEGylated formulations. Age-matched naïve mice were also 
inoculated with MC38 tumor cells for comparative purposes, but mice in this group grew 
tumors slower than some mice in prophylactically vaccinated groups. Though 
interesting, this observation should not be one of concern because naïve control median 
survival was 26.5 days, which was similar to the rates of all other groups, and tumor 
challenge was initiated in a prophylactic setting, which is not clinically relevant in the 




Figure 3-20. Tumor growth summary for all treatment groups in prophylactic vaccination study through day 20 after 
tumor inoculation. *P<0.05.  
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Figure 3-21. Kaplan-Meier overall survival curve for all treatment groups in prophylactic study. No significant 
differences in survival were observed.  
Moving forward, future studies should explore the anti-tumor efficacy of these 
different formulations in a therapeutic setting through vaccination of tumor-bearing mice. 
This prophylactic study has shown us that the simplified, PEGylated neoantigen-sHDL 
formulations induce neoantigen-specific CD8+ T cells and elicit anti-tumor protective 
immunity similarly to traditional formulations, justifying peptide PEGylation as a viable 
method for streamlining nanovaccine formulation. However, prophylactic vaccination is 
not realistic in the context of most cancers and cannot accurately capture the 
interactions between vaccination-induced immune populations and the tumor itself. 
Thus, more meaningful comparisons between PEGylated and traditional formulations’ 
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effects on tumor growth and survival of tumor-bearing mice may be made through 
execution of a therapeutic vaccination study. Additionally, neoantigens derived from 
different tumor models should be evaluated for immunogenicity and anti-tumor efficacy 
using the PEGylated formulation methodology to establish that the method is versatile 
and robust for clinical translation of a personalized cancer vaccination platform. 
  
 
Chapter 4. Synthetic HDL nanoparticles delivering docetaxel 
and CpG for chemo-immuno-therapy of colon carcinoma 
4.1. Abstract 
Colon carcinomas themselves comprise over two-thirds of all colorectal cancers with 
an overall 5-year survival rate of 64%, which rapidly decreases to 14% when the cancer 
becomes distant or metastatic, usually progressing into the liver. Depending on the 
stage of colon carcinoma at diagnosis, patients can undergo surgery to attempt tumor 
resection or move directly to chemotherapy with one or a combination of drugs. As with 
most cancers, colon carcinomas do not always respond to chemotherapies, so targeted 
therapies and immunotherapies have been developed to aid chemotherapy.  
Approved targeted therapies for colon carcinoma are limited to protein inhibitors that 
aim to prevent new blood vessel formation around the tumor or to interrupt tumor cell 
proliferation so that tumor growth can be slowed but do not directly induce tumor cell 
killing. Immunotherapies like anti-CTLA-4 and anti-PD-1 prevent T cell death, allowing 
for increased T cell activation and tumor recognition for indirect tumor cell killing105. 
Unfortunately, these targeted therapies and immunotherapies are associated with 
several adverse events due to their systemic or oral administration.  
 
In this work, we have developed a localized combination therapy for colon 
carcinoma whereby chemo- and immuno-therapeutic entities are delivered to the tumor 
on the same delivery vehicle for maximal anti-tumor efficacy and minimal off-target 
effects. We first encapsulated chemotherapeutic docetaxel (DTX) into the hydrophobic 
core of synthetic HDL (sHDL) nanodiscs and then co-loaded cholesterol-modified Toll-
like receptor 9 (TLR9) agonist CpG (cho-CpG) oligonucleotide onto the surface of 
sHDLs. DLS analysis showed that DTX-loaded sHDLs averaged a particle size of 11.1 
nm, similar to that of blank sHDLs, and that insertion of cho-CpG slightly increased the 
particle size to 11.3 nm. An in vitro cytotoxicity assay showed that murine MC38 colon 
carcinoma cells incubated with free DTX or DTX-loaded sHDL (DTX-sHDL) for 48 hours 
experienced cell death at similar rates. In vivo survival analysis of MC38 tumor-bearing 
mice treated intratumorally with DTX-sHDL/CpG (median survival = 43 days) showed 
significant improvement in overall survival compared to mice treated with DTX (median 
survival = 23 days, p <0.0001) or DTX-sHDL (median survival = 28 days, p<0.0001). 
Two of seven mice treated with DTX-sHDL/CpG experienced complete tumor 
regression. None of the mice experienced any systemic toxicity as indicated by body 
weight maintenance and normal serum enzyme and protein levels. In total, we have 
demonstrated that chemo- and immuno-therapies can be co-loaded into sHDLs, 
delivered locally to the tumor, and improve survival outcomes significantly compared to 
chemotherapy alone.  
4.2. Introduction 
Colon adenocarcinomas constitute the vast majority of all diagnosed colorectal 
cancer cases with an incidence rate of more than 140,000 people per year. Although 
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the average 5-year survival rate for patients diagnosed with colorectal cancer is greater 
than 60%, colorectal cancer remains the 2nd leading cause of death in the United 
States133. This is likely due to nearly half of treated patients developing recurrent 
disease. Currently, the standard-of-care for patients with colon adenocarcinoma is 
surgery, radiation, chemotherapy, and possibly immunotherapy via immune checkpoint 
blockade. Though effective, both chemotherapy and immune checkpoint blockade 
agents are administered systemically and are delivered to the tumor itself in a very 
limited amount. Moreover, neither chemotherapy nor immune checkpoint blockade 
directly elicits immune memory against the tumor, which is crucial for preventing tumor 
recurrence. Thus, combining chemotherapy with an immuno-stimulatory agent that 
promotes immune cell interaction with tumor antigens is an exciting strategy that is 
readily translational and beginning to be explored134,135. 
 We hypothesize that sHDL encapsulating docetaxel chemotherapy and 
decorated with toll-like receptor 9 (TLR9) agonist CpG oligonucleotide delivery to colon 
adenocarcinoma tumors will effectively suppress tumor growth and result in long-term 
survival as compared to monotherapy delivery. TLR9 agonists interact with their 
receptors on a plethora of immune cells and are primarily involved in activation and 
maturation of dendritic cells and differentiation of B cells. These dendritic cells and B 
cells can then undergo cross-presentation of tumor-specific antigens and secretion of 
anti-tumor antibodies, respectively136,137. The source of these antigens often comes 
from apoptotic tumor cells, which can be directly produced by chemotherapeutic 
cytolysis (Figure 4-1). We have previously reported the combination of CpG with 
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chemotherapy for the treatment of glioblastoma and, given the promising results of this 




Figure 4-1. Graphical representation of hypothesis that co-delivery of chemo- and immuno-therapeutic entities will 
synergistically elicit anti-tumor efficacy. 
Several nanoparticles have been used for co-delivery of these two moieties, but 
none of them have been approved for clinical use. In the early 2000s, Weigel et al. 
published data showing the enhanced antitumor effects of cyclophosphamide and 
topotecan when combined with CpG in mouse models of embryonal 
rhabdomyosarcoma. Almost a decade later, Buhtoiarov et al. demonstrated that co-
delivery of CpG with vincristine, cyclophosphamide and doxorubicin in murine 
melanoma and neuroblastoma models significantly improved the antitumor effects of 
multidrug chemotherapy regimens alone. In 2015, Lollo et al. used lipid nanocapsules 
with a cationic chitosan shell to deliver paclitaxel and CpG simultaneously to 
glioblastoma tumors in mice through convection-enhanced delivery and showed that 
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this co-delivery significantly improved survival outcomes compared to Taxol® and 
separate injections of paclitaxel and CpG138-140. sHDL has already been demonstrated 
as safe and well-tolerated in high doses in the clinic, making it a readily translatable 
platform for co-delivered combination therapy for colon adenocarcinoma patients. Here, 
we describe the superior antitumor efficacy of co-delivering docetaxel chemotherapy 
and TLR9 agonist CpG on sHDL nanoparticles to tumors over docetaxel alone.  
4.3. Materials & Methods 
4.3.1. Materials 
Egg sphingomyelin (eSM) was acquired from Avanti Polar Lipids. Apolipoprotein A-1 
mimetic peptide 22A was acquired from GenScript Inc. Docetaxel (DTX) was acquired 
from Cayman Chemicals. MC38 cells were purchased from Kerafast, Inc. Cholesterol-
modified CpG1826 was custom ordered from Integrated DNA Technologies.  
4.3.2. Formulation and characterization of DTX-sHDL 
The docetaxel-loaded sHDL (DTX-sHDL) was prepared as described previously137. 
Briefly, 22A, egg sphingomyelin (eSM) and DTX were dissolved in acetic acid. The 
acetic acid solutions of 22A, eSM and DTX were mixed and freeze-dried for 24 h (mass 
ratio of 22A: eSM: DTX = 1:2:0.05). The lyophilized powder was rehydrated by PBS (pH 
7.4). 3 heat-cooling cycles (50°C 5 min followed by room temperature 5 min) were 
performed to form DTX-sHDL. DTX-sHDL/CpG particles were prepared by incubating 
DTX-sHDL with cholesterol-CpG in 10 mM phosphate buffer at the room temperature 
for 2 h. The particle size of DTX-sHDL was analyzed by dynamic laser scattering (DLS). 
The purity of the DTX-sHDL nanoparticles was evaluated by gel permeation 
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chromatography (GPC) at 220 nm using Tosoh TSK gel G3000SWx 7.8 mm× 30 cm 
column (Tosoh Bioscience, King of Prussia, PA).  
4.3.3. In vitro uptake assays 
MC38 cells were cultured in RPMI medium supplemented with 10% Fetal Bovine 
Serum and 1% Penicillin/Streptomycin antibiotics. When cells reached their exponential 
growth phase, they were trypsinized and plated on 12-well tissue culture plates at 
50,000 cells per well to be incubated overnight at 37C to allow adherence. HDL was 
labeled with lipophilic dye DiD at a ratio of 2:1:0.01 eSM:22A:DiD. DiD-labeled sHDL 
was passed through a desalting column (MWCO 7kDa) to remove free dye molecules 
prior to use.  
Cells were dosed with three different concentrations of DiD-sHDL normalized by 
22A concentration to evaluate the effect of dose on cell uptake. Following dosing, cells 
were incubated at 37C for 3 hours and then washed with PBS before analysis by 
confocal microscopy on a Nikon A1si confocal microscope or by FACS on a CytoFlex 
cytometer. FlowJo and ImageJ were used for quantitative analysis.  
For the Block lipid transport-1 (BLT-1) inhibition experiment, cells were 
pretreated with SR-B1 inhibitor BLT-1 with different concentrations for 1 h. Then, DiD-
sHDL was added to each well (final 22A concentration = 10 μg/mL). The cells were 
further incubated for 3 hours followed by FACS analysis. 
4.3.4. In vitro cytotoxicity assay 
MC38 cells were cultured in RPMI medium supplemented with 10% Fetal Bovine 
Serum and 1% Penicillin/Streptomycin antibiotics. When cells reached their exponential 
growth phase, they were trypsinized and plated on 96-well tissue culture plates at 
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10,000 cells per well to be incubated overnight at 37C to allow adherence. Cells were 
dosed with six different doses of DTX in either free drug form or encapsulated in HDL to 
test the effect of increasing dose on cell death. Following dosing, cells were incubated 
at 37C for 48 hours before analysis using the CellTiter 96® Aqueous Non-Radioactive 
Cell Proliferation Assay (MTS) from Promega. Absorbance at 490 nm was quantified 
using a BioTek SynergyNEO spectrophotometer. Negative control wells (without 
treatment) were considered to have the maximum absorbance at 100% viability, and 
viability of other wells was calculated as the ratio of treated well absorbance to 
untreated well absorbance. 
4.3.5. Western blot of SR-B1 expression on murine cancer cells 
Four different murine cancer cell lines--MC38, B16-F10, CT-26, and 4T1--were 
cultured, trypsinized, and spun down so that cell pellets could be collected and flash 
frozen. Cell lysates were prepared and centrifuged at 16,000 x g for 20 minutes at 4C. 
Supernatant was collected and stored on ice to perform total protein quantification by 
BCA assay. Samples were normalized to 30 µg total protein for loading onto an SDS-
PAGE gel. The gel was run, transferred, and incubated with SR-B1 and actin primary 
antibodies overnight at 4C followed by incubation with HRP-conjugated secondary 
antibody at room temperature. The gel was imaged using a BioRad chemiluminescent 
imager and analyzed with ImageJ.  
4.3.6. In vivo treatment using combination chemotherapy and immunotherapy 
Thirty-five female C57BL/6 mice aged 7-8 weeks (Charles River Laboratories) 
were inoculated with 1 million MC38 cells at a concentration of 10 million cells/mL 
subcutaneously superior to the right flank. On day 8 after tumor inoculation, mice were 
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split into four groups of seven for treatments. Mice were injected intratumorally with (1) 
PBS, (2) DTX, (3) DTX-HDL, or (4) DTX-HDL/CpG twice a week at 1 mg/kg DTX and 15 
µg CpG for five treatments. Mice were euthanized when tumors surpassed 15 mm in 
one dimension or ulcerated extensively.  
4.3.7. Systemic toxicity assessment of chemotherapy and immunotherapy  
Mouse body weights were measured regularly to monitor toxicity-associated weight 
loss. Blood samples were taken four days after the final treatments were administered 
for serum isolation, and liver enzymes were measured by the In-Vivo Animal Core 
Animal Diagnostic Laboratory for further analysis. Livers were excised upon 
euthanization and cryopreserved for histological analysis. Livers were embedded in 
OCT compound, flash frozen, and cut into 8 micrometer sections at -10°C on a cryostat 
(ThermoFisher Scientific, Dr. Megan Weivoda lab). 
4.3.8. Statistical analysis 
Analyses of ELISPOT, FACS, and tumor growth were executed using one-way 
ANOVA tests with Tukey’s post-hoc analyses for multiple comparisons and two-tailed t-
tests for individual group comparisons, all at an alpha level of 0.05. Analyses of survival 
differences were executed using Kaplan-Meier survival analyses with Log-rank Mantel-
Cox tests at an alpha level of 0.05.  
4.4. Results 
4.4.1. Drug and adjuvant loading into sHDL do not affect size or shape of sHDL. 
DTX is loaded in sHDL particles using a simple co-lyophilization/rehydration method 
as described previously. DLS analysis showed that DTX-loaded sHDLs have an 
average particle size of 11.1 nm, which is similar to that of blank sHDL particles. 
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Insertion of cho-CpG slightly increased the particle size to 11.3 nm (Figure 4-2). All 
formulations demonstrated a high purity (> 90%) in GPC analysis (Figure 4-3). The 
consistent size of DTX-loaded sHDL both before and after loading of DTX and cho-CpG 
in conjunction with high formulation purity were satisfactory, allowing us to proceed with 
in vitro and in vivo studies.  
 
Figure 4-2. Dynamic light scattering (DLS) analysis of blank sHDL (black curve), DTX-sHDL (blue curve), DTX-




Figure 4-3. Gel permeation chromatography (GPC) analysis of blank sHDL (black curve), DTX-sHDL (blue curve), 
DTX-sHDL/CpG (green curve). 
 
Figure 4-4. Transmission electron microscopy (TEM) images of DTX-sHDL (A) and DTX-sHDL/CpG (B) particles. 
4.4.2. SR-B1 is highly expressed by MC38 cells and plays a role in cellular 
uptake of sHDL.  
To validate our choice of colon cancer model for evaluating our DTX-loaded sHDL 
formulations, we looked at MC38 cells’ SR-B1 expression level to verify that sHDL could 
be recognized and endocytosed by MC38 cells. Western blot analysis of MC38 cell 
lysate showed high expression of SR-B1 relative to actin band density. This SR-B1 
expression level was comparable to that of other tumor cell lines with known increased 
expression of SR-B1141 (Figure 4-5A). We then looked at sHDL uptake by MC38 cells in 
vitro to gather quantitative evidence that MC38 cells will readily scavenge sHDL in real 
time. When cultured with DiD-labeled sHDL for three hours, MC38 cells exhibited dose-
dependent uptake of sHDL (Figure 4-5B, Figure 4-6A). To confirm that SR-B1 played a 
role in this uptake, we inhibited the SR-B1 on MC38 cells by adding Block lipid 




for 3 hours. Indeed, we observed a marked decrease in cellular uptake of sHDL with 
increasing pretreatment doses of BLT-1 (p < 0.01) (Figure 4-6B). Together, these 
results support our choice of an MC38 cancer model because of high cellular SR-B1 
expression and efficient cellular uptake of sHDL.  
 
Figure 4-5. Cell uptake of sHDL by MC38 cells. (A) Western blot analysis of SR-B1 expression by four cancer cell 
lines: CT26, MC38, 4T1, B16F10. (B) Confocal microscope images of DiD-labeled sHDL by MC38 cells at three 
different concentrations. 
 
Figure 4-6. (A) Quantitative analysis of DiD-labeled sHDL uptake by MC38 cells. (B) Quantitative analysis of DiD-
labeled sHDL uptake by MC38 cells when pre-incubated with SR-B1 blocking molecule BLT-1. 
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4.4.3. Delivery of DTX by sHDL maintains the cytotoxic effect of DTX on MC38 
cells.  
Now that we validated the sHDL scavenging potential of MC38 cells, we tested 
the cytotoxic potential of DTX-loaded sHDL on MC38 cells in vitro. After 48 hours of 
incubation with free DTX or DTX-loaded sHDL (DTX-sHDL), MC38 cells were analyzed 
by MTT assay using a UV spectrophotometer. We observed no significant differences in 
cytotoxicity at higher doses of DTX between the two treatment groups. DTX-sHDL 
induced cell death at a similar rate to DTX alone after just 48 hours in doses of 16 and 
24 micrograms per ~50,000 cells (Figure 4-7).  
 
Figure 4-7. Cytotoxicity analysis of MC38 cells incubated for 48 hours in a 96-well plate with either free DTX or DTX-
sHDL at different drug molecule concentrations. 




































4.4.4. Combination of immuno-stimulatory agent with DTX increases antitumor 
effects and prolongs survival.  
While we have demonstrated that sHDL enhances the delivery of DTX in vitro, 
single-agent therapy is often insufficient for total eradication of the tumor, especially in 
colon adenocarcinoma. Thus, we decided to incorporate immunostimulatory agent 
CpG1826 into our DTX-sHDL formulation to test the efficacy of combination therapy 
relative to single-agent chemotherapy and to determine whether this additional 
component would augment sHDL’s delivery enhancement of DTX in vivo. We observed 
significantly reduced tumor growth in mice treated with DTX-sHDL/CpG compared to 
DTX-sHDL and DTX alone with no differences between DTX and DTX-sHDL groups 
themselves, indicating the enhanced antitumor effect of combination therapy (Figure 
4-9A). We also saw that mice treated with DTX-sHDL/CpG survived significantly longer 
(median survival = 43 days) (p < 0.0001) than mice treated with DTX-sHDL (median 
survival = 28 days) and DTX alone (median survival = 23 days) (Figure 4-9B). Two of 
seven mice treated with DTX-sHDL/CpG experienced complete tumor regression. None 
of the mice experienced any systemic toxicity as indicated by body weight maintenance, 
normal serum enzyme and protein levels, and consistent liver morphology with control 
(Figure 4-10). Overall, we learned that combining immunostimulatory agent CpG1826 
with DTX-sHDL significantly improved survival as compared to single agent 




Figure 4-8. Treatment regimen and timeline of therapeutic animal study. 
 
Figure 4-9.(A) Average tumor growth curves for mice treated with PBS (blue), DTX (red), DTX-sHDL (green), and 
DTX-sHDL/CpG (purple). Error bars represent SEM. (B) Kaplan-Meier survival curves for mice treated with PBS 
(blue), DTX (red), DTX-sHDL (green), and DTX-sHDL/CpG (purple). ****P<0.0001.  
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Figure 4-10. (A) Body weight measurements for study duration. (B) Liver panel toxicity analysis of aspartate 
aminotransferase (AST), albumin (ALB), alanine aminotransferase (ALT), total bilirubin (TBIL), and alkaline 
phosphatase (ALP). (C) H&E staining of liver sections from mice treated with each of the four treatments used in this 
study. Scale bars represent 20 microns.  
4.5. Discussion 
In this work, we hypothesized 1) that sHDL encapsulating docetaxel chemotherapy 
would enhance the delivery of docetaxel to target colon adenocarcinoma cells and 2) 
that combining this single-agent therapy with TLR9 agonist CpG would augment the 
antitumor efficacy of the monotherapy, suppressing tumor growth and prolonging 
survival. Through several in vitro experiments, we showed that sHDL uptake by MC38 
cells is indeed mediated by SR-B1, which is highly expressed on these cells. MC38 
cells exhibited a large capacity for sHDLs as evidenced by quantitative FACS 
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identification of sHDL-positive cells and qualitative confocal microscopy images. These 
findings agree with the current literature that has shown high SR-B1 expression allows 
for greater accumulation of cholesterol in tumor cells via HDL uptake to prolong tumor 
cell survival33,141. Following incubation of MC38 cells with either free DTX or DTX-sHDL, 
we observed that DTX-sHDL induced cell death at a similar rate to DTX at multiple dose 
levels. This result supports the hypothesis that sHDL can delivery DTX to tumor cells 
without compromising the cytotoxic activity of DTX, which potentiates the clinical 
translation of sHDL nanoparticles as drug delivery vehicles for hydrophobic 
chemotherapeutic molecules. We tested our formulation in vivo with an additional 
immunostimulatory component, CpG oligonucleotide. Indeed, CpG significantly 
improved the antitumor efficacy of DTX, suppressing tumor growth and prolonging 
survival in mice treated with DTX-sHDL/CpG as compared to mice treated with DTX-
sHDL or DTX alone. Complete responses were achieved in two of the seven mice 
treated with DTX-sHDL/CpG, supporting the hypothesis that combination therapy with 
an immuno-stimulatory component would augment the antitumor efficacy of DTX alone. 
Interestingly, there were no significant differences in tumor growth or survival between 
the DTX-sHDL and DTX treatment groups. DTX-sHDL treatment marginally improved 
survival rates as compared to DTX treatment, but no differences whatsoever were 
observed in tumor growth rates. These findings disagree with other studies that have 
shown nanoparticle delivery significantly increases delivery of drug molecules to the 
target site. These findings are likely due to the intratumoral route of administration of 
DTX and DTX-sHDL, which does not showcase the tumor targeting abilities of sHDL 
nanoparticles as seen after the intravenous administration 132,137,142.  Larger differences 
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in treatment efficacy between free DTX and DTX-sHDL groups may be better observed 
if the treatments were given intravenously or subcutaneously, both of which could 
demonstrate the superior trafficking abilities of sHDL and its cargo as has been 
demonstrated in the literature90,137,142. Moreover, we only tested one dose of DTX, and it 
is possible that DTX-sHDL may be more effective than free DTX at lower doses. 
Additionally, a deeper mechanistic understanding of this combination therapy is needed 
through delineating the individual therapeutic contributions of free DTX versus free CpG 
and by testing this platform in an orthotopic mouse model.  
Nonetheless, we have described the superior antitumor efficacy of co-delivering 
docetaxel chemotherapy and TLR9 agonist CpG on sHDL nanoparticles to MC-38 colon 
adenocarcinoma tumors when compared to docetaxel alone.  Our findings are 
significant because sHDL has already been demonstrated to be safe and well-tolerated 
in high doses in the clinic, making it a readily translatable platform for co-delivered 
combination therapy for colon adenocarcinoma patients. Indeed, no systemic toxicity 
was elicited by the sHDL-DTX-CpG treatment. We have also shown that this platform is 
translatable to other cancers as it has been previously effective in a glioblastoma 
model137. Our results give promise to the evolution of highly effective, minimally 




Chapter 5. Conclusions & Perspectives 
Within this dissertation, we have explored (1) the therapeutic ability of sHDL 
nanodiscs to deliver neoantigens for glioblastoma multiforme to exert robust anti-tumor 
effects, (2) the retention of immunogenicity of colon adenocarcinoma neoantigen-loaded 
sHDL nanodiscs following formulation simplification, and (3) the ability of sHDL 
nanodiscs to co-deliver chemo- and immuno-therapeutic entities to colon 
adenocarcinoma tumors.   
In the first project, we found that delivery of neoantigens by sHDL nanodisc was 
significantly more effective compared to delivery of soluble neoantigens in neoantigen-
specific CD8+ T cell production, tumor growth reduction, and survival prolongation in 
murine glioblastoma multiforme models.  Interestingly, while NeoAg-3-specific CD8+ T 
cell frequencies were not significantly different between mice treated with nanovaccine 
+/- anti-PD-L1 and mice treated with soluble NeoAgs +/- anti-PD-L1, possibly due to 
competitive binding to MHC-I between NeoAg-1 and NeoAg-3. Future investigation of 
this hypothesis should be considered to determine whether inclusion of NeoAg-3 in the 
nanovaccine is substantiated. Anti-tumor effects were augmented by the addition of 
immune checkpoint blockade using anti-PD-L1, supporting the current opinion 
surrounding cancer treatment that combination therapy, namely immunotherapy, will be 
the most effective approach to reducing patient tumor burden and prolonging survival 
 
moving forward. Moreover, treating glioblastoma tumor-bearing mice with our 
neoantigen-loaded sHDL nanovaccine in combination with anti-PD-L1 was able to 
reverse immunosuppression within the tumor microenvironment as indicated by 
significant increases in CD8+ T cells and concomitant decreases in PD-1 expression on 
CD8+ T cells and Treg frequencies within the tumor. Long-term survivors that were 
rechallenged with tumor cells in the opposite flank or hemisphere did not experience 
tumor recurrence, evidencing establishment of anti-tumor immune memory. Future 
studies on this work should investigate the cytokine profiles within the tumor 
microenvironment to support reversal of immunosuppression, evaluate immune memory 
cell characteristics to determine whether memory is generated by all three neoantigens 
equally and when it is generated, and to test the nanovaccine in combination with other 
immune checkpoint blockades in the orthotopic model. The hypothesis proposed 
regarding immune tolerance induction by soluble neoantigens would also be interesting 
to test to support further the use of sHDL as a delivery vehicle for antigens and 
adjuvants. 
In the second project, we showed that we were able to simplify our formulation 
process for neoantigen-loaded sHDL through chemical modification of two neoantigen 
peptides using short chain PEG and pre-made lipoprotein films. We verified that the 
simplified PEGylated formulations induced neoantigen-specific CD8+ T cell expansion 
similar to our traditional formulations, substantiating the overarching goal of the project 
to streamline personalized vaccination formulations for clinical translation.  Although 
prophylactic vaccination did not slow MC38 tumor growth equally between the two 
neoantigens Reps1 and Adpgk, we did see that PEGylated formulations and traditional 
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formulations exhibited anti-tumor efficacy similar to each other. Adpgk formulations 
were better able to slow tumor growth and prolong overall survival of tumor-challenged 
mice than were Reps1 formulations, which indicates that our MC38 cell line expressed 
Reps1 at much lower levels than Adpgk. Future studies on this work should include 
tumor challenge of prophylactically Reps1-vaccinated mice with MC38 cells expressing 
higher levels of Reps1, therapeutic vaccination of tumor-bearing mice with PEGylated 
formulations, and evaluation of different tumor models using nanovaccine formulations 
of other PEGylated neoantigens. The data from these studies will tell us whether 
PEGylating neoantigen peptides for aqueous sHDL nanodisc loading will improve 
process efficiency for multiple cancers while retaining nanovaccine anti-tumor activity. 
Scalability of PEGylated peptide and conjugate lipid synthesis should also be tested as 
large-scale manufacturing of sHDL has already been done successfully.  
In the third project, we demonstrated the superior anti-tumor efficacy of co-delivering   
chemo- and immune-therapeutic entities on sHDL nanodiscs in a murine colon 
carcinoma model.  In vitro cytotoxicity assays of MC38 cells incubated with either free 
DTX or DTX-sHDL revealed that DTX-sHDL induced cell death at a similar rate to DTX 
at multiple dose levels, supporting the hypothesis that sHDL can delivery DTX to tumor 
cells without compromising the cytotoxic activity of DTX and potentiating the clinical 
translation of sHDLs as drug delivery vehicles for chemotherapeutic molecules. In vivo 
evaluation of DTX-sHDL co-loaded with CpG oligonucleotide revealed that CpG 
significantly improved the antitumor efficacy of DTX, suppressing tumor growth and 
prolonging survival in mice treated with DTX-sHDL/CpG as compared to mice treated 
with DTX-sHDL or DTX alone. Complete responses were achieved in two of the seven 
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mice treated with DTX-sHDL/CpG, supporting the hypothesis that combination therapy 
with an immuno-stimulatory component would augment the antitumor efficacy of 
chemotherapy alone. Future studies on this work should include exploration of different 
routes of administration, as the intratumoral route is not realistic in all cases and types 
of cancer, in a variety of tumor models and also evaluation of different 
chemotherapeutic and immunotherapeutic entities because patient responses to 
specific drugs are quite heterogenous. Evaluation of the tumor microenvironment would 
also be interesting to determine whether the combination of chemo- and immuno-
therapies alters the immune cell population within the tumor significantly compared to 
single therapeutic agents.  
In full, this dissertation has (1) exposed a highly efficacious, tumor-specific, and 
personalized nanovaccine design for improving treatment of patients with GBM, (2) 
streamlined the neoantigen-sHDL nanovaccine formulation process for clinical 
translation, and (3) proposed an efficient method for co-delivery of chemo- and immuno-
therapeutic entities for site-specific, non-toxic cancer treatment using sHDL nanodiscs. 
We believe that sHDL nanodiscs are versatile drug delivery vehicles and could set the 
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